October19–22, 2016

Congress Center HamburgGermany

Final Programme

2

6th European Congress of Virology

3

Content Page

Words of Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 5

Committees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 8

Plenary / Keynote Lecturers. . . . . . . . . . . . . . . . . . . . . . . . P. 10

Chairpersons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 11

Awards/Travel Grant Winners . . . . . . . . . . . . . . . . . . . . . . P. 13

General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 15

Programme Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 16

Detailed Programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 20

Poster Exhibition and Poster Sessions. . . . . . . . . . . . . . . . P. 33

Poster Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 34

Speaker’s Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 47

Congess Dinner & Networking Event . . . . . . . . . . . . . . . . P. 52

Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 53

Sponsors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 55

Exhibition List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 56

Exhibition Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 57

Congress Center Hamburg Overview . . . . . . . . . . . . . . . . P. 59

Notes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P. 60

Imprint

Organisers:

European Society for Virology (ESV)

Heinrich Pette Institute,Leibniz Institute for Experimental Virology

Conference Chair:

Prof. Joachim Hauber

Heinrich Pette InstituteLeibniz Institute for Experimental Virology Martinistraße 5220251 Hamburg, GermanyE-mail: ecv2016@hpi.uni-hamburg.deWeb: www.hpi-hamburg.de

Congress Organisation, Exhibition & Sponsoring, Congress Dinner:

INTERPLAN Congress, Meeting& Event Management AGRebecca LefersKaiser-Wilhelm-Str. 9320355 Hamburg, GermanyE-mail: ecv2016@interplan.deWeb: www.interplan.de

Advertsing:

Bernhard Nocht Institute for Tropical Medicine

Centre for Structural Systems Biology

Fraunhofer IME ScreeningPort

Heinrich Pette Institute, Leibniz Institute for Experimental Virology

Life Science Nord Management GmbH

MSD SHARP & DOHME GMBH

QIAGEN GmbH

Takara Bio Europe

Zymo Research Europe GmbH

4

6th European Congress of Virology

5

Words of Welcome

Dear attendees, dear colleagues and dear friends,

Welcome to the Free and Hanseatic City of Hamburg, the site of the

6th European Congress of Virology (ECV2016). Your presence here is

highly appreciated and greatly enhances the intellectual and social

vibrancy of the conference.

The ECV2016 couldn’t take place at a more appropriate or better

time, from 19-22 October 2016. Just to give a few examples, the fre-

quent emergence or re-emergence of zoonotic or vector-borne viral

diseases, such as Zika, Ebola or MERS-CoV, the clinical implementa-

tion of a truly curative strategy for HCV infection, or the development

of novel and stunning genome editing technologies, which may soon

allow the direct targeting and subsequent eradication of persistent

viruses, has recently moved virology, the fi eld of our professional in-

terest, into greater focus within society in general.

In the light of such exceptional scientifi c and clinical developments, it is the intention of the organiz-

ers, the European Society of Virology (ESV) and, locally, the Heinrich Pette Institute, Leibniz Institute for

Experimental Virology (HPI), that this congress effectively bridges the various aspects of basic, transla-

tional, clinical, veterinary and plant virology. We strongly believe that the programme of ECV2016 will

inspire early, mid and late-career virologists alike.

Such an event cannot be organized without external sponsorship. We therefore greatly appreciate the

fi nancial support of corporations and foundations. Without them, ECV2016 wouldn’t be such a vibrant

event. You should defi nitively visit the fully integrated ECV2016 sponsor exhibition area.

The venue, the Congress Center Hamburg (CCH), is located right in the centre of Hamburg, Germany’s

youthful and tolerant waterside metropolis. Please enjoy the 6th European Congress of Virology and this

outstanding location during your visit.

On behalf of the Local Organizing Committee

Joachim Hauber

President of ECV2016

6

6th European Congress of Virology

7

Words of Welcome

Dear colleagues,

In the occasion of the 6th European Congress of Virology (ECV2016),

it is my great pleasure to welcome you and to illustrate the aim of the

European Society for Virology (ESV).

ESV provides a forum for scientists active in all aspects of Virology.

The aim of the Society is to advance the art and science of Virology

and to promote and stimulate the exchange of information and col-

laboration among individual scientists as well as among national and

international associations of Virology throughout Europe.

As in the previous editions, ECV will cover many topics of Virology,

providing insights into molecular pathogenesis, structural biology,

infection and immunity, epidemiology, advanced therapies and pre-

vention, biotechnology. Talks will be presented by keynote speakers

of indisputable reputation and the scientifi c programme is really out-

standing. Furthermore, this ECV will be the perfect opportunity for reinforcing or setting up old and new

collaborations among European virologists.

In addition to the scientifi c aspects, ECV will also be instrumental for the growth of our Society by voting

the new governing boards, by deciding the seats of future ECVs, by proposing new strategies in order to

generate new professional opportunities and make Virology in Europe more attractive for young investi-

gators and infl uential at all Institutional levels.

While sincerely thanking you for your participation, I wish you a stimulating, fruitful and enjoyable 6th

European Congress of Virology.

Giorgio Palù

President ESV

6th European Congress of Virology

Commi� ees

Scientifi c Committee

Allen, Todd Cambridge MA, USA

Altfeld, Marcus Hamburg, Germany

Berkhout, Ben Amsterdam, The Netherlands

Blanc, Stéphane Montpellier, France

Brune, Wolfram Hamburg, Germany

Cadar, Daniel Hamburg, Germany

Campadelli-Fiume, Gabriella Bologna, Italy

Cullen, Bryan R. Durham NC, USA

Delwart, Eric San Francisco CA, USA

Dobner, Thomas Hamburg, Germany

Drosten, Christian Bonn, Germany

Eberhard, Johanna M. Hamburg, Germany

Feldmann, Heinz Hamilton MT, USA

Fischer, Nicole Hamburg, Germany

Fleckenstein, Bernhard Erlangen, Germany

Frahm, Thomas Hamburg, Germany

Gabriel, Gülsah Hamburg, Germany

Geijtenbeek, Teunis B. Amsterdam, The Netherlands

Greber, Urs Zurich, Switzerland

Grünewald, Kay Hamburg, Germany

Günther, Stefan Hamburg, Germany

Haberl, Annette Frankfurt, Germany

Harrer, Thomas Erlangen, Germany

Herker, Eva Hamburg, Germany

Hirsch, Hans Basel, Switzerland

Kaiser, Rolf Cologne, Germany

Klein, Florian Cologne, Germany

Koopmans, Marion Rotterdam, The Netherlands

Local Organizing Committee

Haller, Kerstin Heinrich Pette Institute, Hamburg, Germany

Hauber, Joachim Heinrich Pette Institute, Hamburg, Germany

Neumann, Ute Heinrich Pette Institute, Hamburg, Germany

Schewe, Knud Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany

Schulze zur Wiesch, Julian University Medical Center Eppendorf, Hamburg, Germany

8

Kräusslich, Hans-Georg Heidelberg, Germany

Lavillette, Dimitri Shanghai, China

Liljeström, Peter Stockholm, Sweden

Malim, Michael H. London, UK

Masucci, Maria G. Stockholm, Sweden

Mettenleiter, Thomas Greifswald, Germany

Mölling, Karin Berlin, Germany

Palù, Giorgio Padova, Italy

Pantaleo, Guiseppe Lausanne, Switzerland

Parissi, Vincent Bordeaux, France

Puchhammer, Elisabeth Vienna, Austria

Rey, Félix A. Paris, France

Rivas, Carmen Madrid, Spain

Rockstroh, Jürgen Bonn, Germany

Schulz, Thomas Hannover, Germany

Schulze zur Wiesch, Julian Hamburg, Germany

Sodeik, Beate Hannover, Germany

Stellbrink, Hans-Jürgen Hamburg, Germany

Sutter, Gerd Munich, Germany

Tannich, Egbert Hamburg, Germany

Tommasino, Massimo Lyon, France

Tordo, Noël Paris, France

Trkola, Alexandra Zurich, Switzerland

Uetrecht, Charlotte Hamburg, Germany

van der Poel, Wim H. Wageningen, The Netherlands

van der Vlugt, René A.A. Wageningen, The Netherlands

Wagner, Ralf Regensburg, Germany

Wolf, Dana Jerusalem, Israel

9

ESV Board Members

President

Palù, Giorgio University of Padova, School of Medicine, Padova, Italy

First Vice-President

Tordo, Noël Institut Pasteur, Paris, France

Second Vice-President

Berkhout, Ben University of Amsterdam, Amsterdam, The Netherlands

Treasurer

Lavillette, Dimitri Institut Pasteur Shanghai, Shanghai, China

Secretary General

Fleckenstein, Bernhard University of Erlangen-Nuremberg, Erlangen, Germany

ESV Advisory Council

Elected Members

Bartenschlager, Ralf University Hospital Heidelberg, Heidelberg, Germany

Domingo, Esteban Universidad Autónoma de Madrid, Cantoblanco, Madrid, Spain

Duprex,W. Paul Boston University School of Medicine, Boston, MA, USA

Greber, Urs University of Zurich, Zurich, Switzerland

Koopmans, Marion Erasmus MC, Rotterdam, The Netherlands

Landolfo, Santo University of Turin, Turin, Italy

Lina, Bruno Centre de Biologie et de Pathologie Est, Lyon, France

Mertens, Thomas University Hospital of Ulm, Ulm, Germany

Mettenleiter, Thomas Friedrich-Loeffl er-Institut, Greifswald-Insel Riems, Germany

Osterhaus, Albert University of Veterinary Medicine Hannover, Hannover, Germany

Svensson, Lennart University of Linköping, Linköping, Sweden

Wolf, Dana Hadassah University Hospital, Jerusalem, Israel

Chairperson of the Award Committee

Skehel, John The Francis Crick Instiute, London, UK

Chairperson of the Meetings Committee

Campadelli-Fiume, Gabriela University of Bologna, Bologna, Italy

6th European Congress of Virology

10

Plenary / Keynote Lecturers:

Todd Allen Ragon Institute of MGH, MIT and Harvard, Cambridge MA, USAGraciela Andrei Rega Institute, KU Leuven, BelgiumRalf Bartenschlager University Hospital Heidelberg, Heidelberg, GermanyThomas F. Baumert INSERM, University of Strasbourg, Strasbourg, FranceMartin Beer Friedrich-Loeffl er-Institute, Greifswald-Insel Riems, GermanyPaul Benn ViiV Healthcare, London, UKClarisse Berlioz-Torrent INSERM, Paris, FranceStéphane Blanc NRA-CIRAD-Supagro, Montpellier, FranceFrank Buchholz TU Dresden, Dresden, GermanyGabriela Campadelli-Fiume University of Bologna, Bologna, ItalyMiles W. Carroll Public Health England, Salisbury, UKSusanna Chiocca European Institute of Oncology, Milano, ItalyBryan R. Cullen Duke University Medical Center, Durham NC, USAWard De Spiegelaere Ghent University, BelgiumEric Delwart University of California, San Francisco CA, USAChristian Drosten University of Bonn, Bonn, GermanyDenis Fargette IRD, Université Montpellier 2, Montpellier, FranceHeinz Feldmann NIAID, NIH, Hamilton MT, USADon Ganem Novartis Institutes for Biomedical Research, Emeryville CA, USAJ. Victor Garcia University of North Carolina, Chapel Hill NC, USATeunis B. Geijtenbeek University of Amsterdam, Amsterdam, The NetherlandsPhilip Goulder University of Oxford, Oxford, UKUrs Greber University of Zurich, Zurich, SwitzerlandHans Hirsch University of Basel, Basel, SwitzerlandMichael J. Imperiale University of Michigan, Ann Arbor MI, USARolf Kaiser University Hospital Cologne, Cologne, GermanyPaul Kellam Welcome Trust Sanger Institute, Cambridge, UKMarion Koopmans Erasmus MC, Rotterdam, The NetherlandsHelen M. Lazear University of North Carolina, Chapel Hill NC, USAPeter Liljeström Karolinska Institutet, Stockholm, SwedenVishwanath R. Lingappa Prosetta Biosciences, San Francisco CA, USAMichael H. Malim King’s College London, London, UKMaria Masucci Karolinska Institutet, Stockholm, SwedenThomas Mettenleiter Friedrich-Loeffl er-Institut, Greifswald-Insel Riems, GermanyChristian Münz University of Zurich, Zurich, SwitzerlandAlbert Osterhaus University of Veterinary Medicine Hannover, Hannover, GermanyGuiseppe Pantaleo University of Lausanne, Lausanne, SwitzerlandAnna Papa Aristotle University of Thessaloniki, Thessaloniki, GreeceSven Pischke University Medical Center Eppendorf, Hamburg, GermanyAlexander Ploss Princeton University, Princeton NJ, USAFélix A. Rey Institut Pasteur, Paris, FranceCarmen Rivas CIMUS USC, Santiago de Compostela, SpainJürgen Rockstroh Bonn University Hospital, Bonn, GermanyMassimo Tommasino International Agency for Research on Cancer, Lyon, FranceNoël Tordo Institut Pasteur, Paris, FranceJonathan Towner CDC, Atlanta GA, USAAlexandra Trkola University of Zurich, Zurich, SwitzerlandStephan Urban University Hospital Heidelberg, Heidelberg, GermanyWim H. van der Poel Wageningen University, Lelystad, The NetherlandsDana Wolf Hadassah Medical Center, Jerusalem, Israel

11

Chairpersons:

Marylyn M. Addo University Medical Center Eppendorf, Hamburg, GermanyTodd Allen Ragon Institute of MGH, MIT and Harvard, Cambridge MA, USAMarcus Altfeld Heinrich Pette Institute, Hamburg, GermanyRalf Bartenschlager University Hospital Heidelberg, Heidelberg, GermanyThomas F. Baumert INSERM, University of Strasbourg, Strasbourg, FranceBen Berkhout University of Amsterdam, Amsterdam, The NetherlandsStéphane Blanc INRA-CIRAD-Supagro, Montpellier, FranceWolfram Brune Heinrich Pette Institute, Hamburg, GermanyDaniel Cadar Bernhard Nocht Institute, Hamburg, GermanyGabriela Campadelli-Fiume University of Bologna, Bologna, ItalyBryan R. Cullen Duke University Medical Center, Durham NC, USAOlaf Degen University Medical Center Eppendorf, Hamburg, GermanyEric Delwart University of California, San Francisco CA, USAThomas Dobner Heinrich Pette Institute, Hamburg, GermanyChristian Drosten University of Bonn, Bonn, GermanyDenis Fargette IRD, Université Montpellier 2, Montpellier, FranceHeinz Feldmann NIAID NIH, Hamilton MT, USANicole Fischer University Medical Center Eppendorf, Hamburg, GermanyBernhard Fleckenstein University of Erlangen-Nürnberg, Erlangen, GermanyGülsah Gabriel Heinrich Pette Institute, Hamburg, GermanyTeunis B. Geijtenbeek University of Amsterdam, Amsterdam, The NetherlandsUrs Greber University of Zurich, Zurich, SwitzerlandStefan Günther Bernhard Nocht Institute, Hamburg, GermanyKay Grünewald Heinrich Pette Institute, Hamburg, GermanyAdam Grundhoff Heinrich Pette Institute, Hamburg, GermanyAnnette Haberl HIVCenter University of Frankfurt, Frankfurt, GermanyThomas Harrer University of Erlangen-Nürnberg, Erlangen, GermanyHans Hirsch University of Basel, Basel, SwitzerlandRolf Kaiser University Hospital Cologne, Cologne, GermanyFlorian Klein University Hospital Cologne, Cologne, GermanyMarion Koopmans Erasmus MC, Rotterdam, The NetherlandsHans-Georg Kräusslich University of Heidelberg, Heidelberg, GermanyDimitri Lavillette Institut Pasteur Shanghai, Shanghai, ChinaUlrike C. Lange University Medical Center Eppendorf, Hamburg, GermanyPeter Liljeström Karolinska Institutet, Stockholm, SwedenMarc Lütgehetmann University Medical Center Eppendorf, Hamburg, GermanyMichael H. Malim King’s College London, London, UKMaria Masucci Karolinska Institutet, Stockholm, SwedenThomas Mettenleiter Friedrich-Loeffl er-Institut, Greifswald-Insel Riems, GermanyKarin Mölling MPI Genetics, Berlin, GermanyCesar Muñoz-Fontela Heinrich Pette Institute, Hamburg, GermanyAlbert Osterhaus University of Veterinary Medicine Hannover, Hannover, GermanyGiorgio Palù University of Padova, Padova, ItalyVincent Parissi CNRS, Bordeaux 2 University, Bordeaux, FranceGuiseppe Pantaleo University of Lausanne, Lausanne, SwitzerlandElisabeth Puchhammer Medical University Vienna, Vienna, AustriaFélix A. Rey Institut Pasteur, Paris, FranceCarmen Rivas CIMUS USC, Santiago de Compostela, SpainJürgen Rockstroh Bonn University Hospital, Bonn, GermanyThomas Schulz Hanover Medical School, Hannover, GermanyJulian Schulze zur Wiesch University Medical Center Eppendorf, Hamburg, GermanyBeate Sodeik Hanover Medical School, Hannover, GermanyHans-Jürgen Stellbrink ICH, Hamburg, GermanyGerd Sutter Ludwig Maximilians University, Munich, GermanyMassimo Tommasino International Agency for Research on Cancer, Lyon, FranceNoël Tordo Institut Pasteur, Paris, FranceAlexandra Trkola University of Zurich, Zurich, SwitzerlandKlaus Überla University of Erlangen-Nürnberg, Erlangen, GermanyWim H. van der Poel Wageningen University, Lelystad, The NetherlandsRené A.A. van der Vlugt Wageningen University, Wageningen, The NetherlandsRalf Wagner University of Regensburg, Regensburg, GermanyDana Wolf Hadassah Medical Center, Jerusalem, Israel

12

6th European Congress of Virology

13

Awards

European Virology Award (EVA) of the European Society of VirologyProf. Ralf BartenschlagerNew insights into the fl avivirus replication cycle: Implications for antiviral treatment and prevention

Zentrum für InfektiologieAbteilung Molekulare VirologieUniversitätsKlinikum Heidelberg

Thursday, 20 October 20165:15 pm – 6:00 pmHall 1 – 2. Floor

Junior Investigator Award of the European Society of VirologyDr. Vincent J. MunsterThe ecology of emerging viruses: From host reservoir to disease

Virus Ecology UnitLaboratory of VirologyRocky Mountain Laboratories, NIAID/NIHHamilton MT

Wednesday, 19 October 20166:15 pm – 7:00 pmHall 1 – 2. Floor

Travel Grant Winners

Congratulations to the winners of a travel grant of the European Society for Virology:Maite Baz-Martínez, Santiago De Compostela, SpainSimon Boudreault, Sherbrooke, CanadaChristiane Anika Bresk, Innsbruck, AustriaCarlos Castaño-Rodriguez, Madrid, SpainMeiling Dai, Utrecht, NetherlandsSandra Dehn, Tübingen, GermanyAlexandra Dudek, Freiburg, GermanySebastien Felt, Charlotte, USAAna Rita Ferreira, Aveiro, PortugalWilhelm Furnon, Lyon, FranceNicole Grandi, Monserrato, ItalyElena Moreno del Olmo, Madrid, SpainAhmed Mesalam, Ghent, BelgiumDominik Schmiedel, Jerusalem, IsraelMathieu Sikorski, Nantes, FranceJulie Tai, Jerusalem, IsraelSu Hui Catherine Teo, London, UKKirstin Vonderstein, Umeå, SwedenYury Zhernov, Moscow, Russia

Congratulations to the winners of a travel grant of the European Society for Veterinary Virology: Fanny Bringolf, Bern, SwitzerlandSabri Hacioglu, Ankara, Turkey Vincent Legros, Paris, France

14

6th European Congress of Virology

15

General Information

Congress Venue

CCH Congress Center HamburgAm Dammtor / Marseiller Strasse20355 HamburgGermany

Opening Hours Registration

Wednesday, 19.10.2016: 11:30 – 19:30Thursday, 20.10.2016: 07:30 – 18:30 Friday, 21.10.2016: 07:30 – 19:00 Saturday, 22.10.2016: 07:30 – 19:00

Opening Hours Exhibition

Wednesday, 19.10.2016: 12:30 – 18:00 Thursday, 20.10.2016: 09:30 – 17:30 Friday, 21.10.2016: 09:30 – 17:00 Saturday, 22.10.2016: 09:30 – 15:00

Accreditation

CME accredited: 33 pointsRecognition of Tierärztekammer Hamburg (vet board) applied.

Posters

Scientifi c posters will be presented in the following topic groups:

Basic Virology: Foyer Hall D-GZonooses, Emerging Infections: Hall D+EClinical Virology: Hall EImmunity: Hall E

There will be Poster Sessions at the poster areas as follows:

Wednesday, 19 October: 18:00 – 20:00Thursday, 20 October: 17:30 – 19:30Friday, 21 October: 17:15 – 19:00

See page 31ff for details.

WiFi

WiFi is available at the congress.

WLAN network: _WIFI_SMS-CCHPassword: wifi 2016cch

You need to enter your country and your mobile phone number and will get a password via SMS which is valid for that day.

The detailed programme is subject to change.

16

6th European Congress of Virology

Programme Overview

Wed

nesd

ay, 1

9th O

ctob

erH

all 1

– 2

. Flo

orH

all F

– 2

. Flo

orH

all A

– 1

. Flo

orH

all B

– 1

. Flo

or

13:0

0W

elco

me

Post

er E

xhib

ition

14:0

0PS

1Th

e Fu

ture

of A

ntiv

iral

Ther

apy

15:0

0

Co

ffee

Bre

ak +

Vis

it In

dus

try

Exh

ibit

ion

16:0

0W

S1In

nate

Ant

ivira

l Im

mun

ity

and

Vira

l Im

mun

e Ev

asio

n

WS2

Rest

rictio

n Fa

ctor

s of

Vira

l In

fect

ion

WS3

Viru

s A

ttac

hmen

t an

d

Entr

y

WS4

Viru

s Re

plic

atio

n St

rate

-g

ies

17:0

0

18:0

018

:15

– 19

:00

ESV

Jun

ior

Inve

stig

ator

Aw

ard

Post

er S

essi

on

19:0

0

17

Thur

sday

, 20th

Oct

ober

Hal

l 1 –

2. F

loor

Hal

l F –

2. F

loor

Hal

l A –

1. F

loor

Hal

l B –

1. F

loor

08:0

0

09:0

0W

S5A

dap

tive

Ant

ivira

l Im

-m

unity

and

Vira

l Im

mun

e Ev

asio

n

WS6

Viru

s M

atur

atio

n an

d

Egre

ss

WS7

Ad

vanc

ed V

irus

Dia

gno

sis

WS8

Vira

l Pat

hog

enes

is

Post

er E

xhib

ition

10:0

0

Co

ffee

Bre

ak +

Vis

it In

dus

try

Exh

ibit

ion

11:0

0PS

2A

nim

al M

odel

s fo

r V

irus

Rese

arch

12:0

0

13:0

0

Lunc

h B

reak

Sy

mp

osi

um:

No

vel T

ech-

nolo

gie

s fo

r Im

pro

ved

P

atho

gen

Det

ecti

on

Lunc

h B

reak

/ V

isit

Ind

ustr

y E

xhib

itio

n14

:00

15:0

0W

S9H

umor

al Im

mun

e Re

spon

se t

o V

iral I

nfec

tion

WS1

0V

irus

Stru

ctur

e an

d Im

ag-

ing

WS1

1A

pp

rove

d A

nti v

iral T

hera

-p

ies

WS1

2Pe

dia

tric

Vira

l Inf

ectio

ns

16:0

0

17:0

017

:15

– 19

:00

EVA

- E

urop

ean

Viro

log

y A

war

dIn

vest

igat

or A

war

d18

:00

Post

er S

essi

on

19:0

0

18

6th European Congress of VirologyFr

iday

, 21st

Oct

ober

Hal

l 1 –

2. F

loor

Hal

l F –

2. F

loor

Hal

l A –

1. F

loor

Hal

l B –

1. F

loor

08:0

0

09:0

0W

S13

Ant

ivira

l Va

ccin

es

WS1

4Em

erg

ing

Top

ics

in V

et-

erin

ary

Viro

log

y

WS1

5O

ncog

enic

Mec

hani

sms

of

Viru

ses

WS1

6V

iral L

aten

cy a

nd P

ersi

s-te

nce

Post

er E

xhib

ition

10:0

0

Co

ffee

Bre

ak +

Vis

it In

dus

try

Exh

ibit

ion

11:0

0PS

3Em

erg

ing

V

irus

Infe

ctio

ns12

:00

13:0

0Lu

nch

Bre

ak

Sym

posi

um:

HB

V a

nd H

IV C

ure

Lunc

h B

reak

/ V

isit

Ind

ustr

y E

xhib

itio

n14

:00

15:0

0W

S17

Exp

erim

enta

l Ant

ivira

l Th

erap

ies

WS1

8H

ighl

y Pa

thog

enic

Viru

ses

WS1

9V

iral G

ene

Exp

ress

ion

– Tr

ansc

riptio

n, T

rans

latio

n

WS2

0V

iral V

ecto

rs fo

r Va

ccin

e D

esig

n16

:00

17:0

0G

ener

al

Ass

embl

y - E

SVPo

ster

Ses

sion

18

:00

19:0

0

Con

gre

ss D

inne

r &

Net

wor

king

Eve

nt20

:00

21:0

022

:00

23:0

0

Programme Overview

19

Satu

rday

, 22nd

Oct

ober

Hal

l 1 –

2. F

loor

Hal

l F –

2. F

loor

Hal

l A –

1. F

loor

Hal

l B –

1. F

loor

08:0

0

09:0

0W

S21

Vira

l Evo

lutio

n an

d R

esis

t-an

ce

WS2

2V

irus

Epid

emio

log

y an

d

Surv

eilla

nce

WS2

3In

fect

ion

of t

he Im

mun

o-co

mp

rom

ised

WS2

4Zo

onot

ic V

iruse

s10

:00

Co

ffee

Bre

ak +

Vis

it In

dus

try

Exh

ibit

ion

11:0

0PS

4N

ext

Gen

erat

ion

Viro

mic

s12

:00

13:0

0Lu

nch

Bre

ak

Sym

po

sium

: Cha

lleng

es

in C

linic

al V

iro

log

ySy

mp

osi

um:

Em

erg

ing

Z

oo

nose

s14

:00

15:0

0W

S25

Cur

ativ

e St

rate

gie

s fo

r V

irus

Erad

icat

ion

WS2

6V

irus

Dis

cove

ry, T

ypin

g

and

Met

agen

omic

s

WS2

7Ve

ctor

Bor

ne In

fect

ions

WS2

8B

est

of P

oste

rs

16:0

0

17:0

0Fa

rew

ell

20

6th European Congress of Virology

Wed

nesd

ay, 1

9th O

ctob

er

13

:30

– 1

5:3

0

Plenary Session 1: The Future of

Antiviral Therapy

13:00 – 13:30 Opening Ceremony – Welcome Session Hall 1 - 2.Floor

Chairpersons Klaus Überla, Erlangen, Germany Olaf Degen, Hamburg, Germany

Hal

l 1 –

2.

Flo

or13:30 – 14:00 Antiviral drug development: Assessing the present, imagining the future

Don Ganem, Emeryville CA, USA14:00 – 14:30 Strategies to manage herpesvirus drug-resistance

Graciela Andrei, Leuven, Belgium14:30 – 15:00 Entry inhibition as a future therapeutic option to treat hepatitis B and

hepatitis D virus infectionStephan Urban, Heidelberg, Germany

15:00 – 15:30 Long-acting injectables for HIV therapy and preventionPaul Benn, London, UK

15:30 – 16:00 Coffee Break Foyer D-G; Hall G, D and E - 2.Floor

16

:00

– 1

8:0

0

WS1: Innate Antiviral Immunity and Viral Immune

Evasion

Chairpersons Marcus Altfeld, Hamburg, Germany Teunis B. Geijtenbeek, Amsterdam, The Netherlands

Hal

l 1 –

2.

Flo

or

16:00 – 16:30 Keynote: How viruses usurp the host cellular machineries to evade innate immune responses: The case of the restriction factor BST2/Tetherin and the HIV-1 protein VpuClarisse Berlioz-Torrent, Paris, France

16:30 – 17:00 Keynote: HIV-1 evades innate sensing by a novel RNA sensor in dendritic cellsTeunis B.H. Geijtenbeek, Amsterdam, The Netherlands

17:00 – 17:15 Cytomegalovirus recruits the retromer complex to promote NEMO degra-dation by autophagyElena Muscolino, Hamburg, Germany

17:15 – 17:30 Human herpesvirus 6 downregulates the expression of activating ligands during lytic infection to escape elimination by natural killer cellsDominik Schmiedel, Jerusalem, Israel

17:30 – 17:45 Antiviral activity of the cGAS-STING pathway against hepatitis B virus i nfectionSeung-Ae Yim, Strasbourg, France

17:45 – 18:00 Membranous fi ngerprinting of HIV-1 infected primary CD4+ T cells reveals virus-mediated dysregulation of a putative NK cell receptorSandra Dehn, Tübingen, Germany

16

:00

– 1

8:0

0

WS2: Restriction

Factors of Viral Infection

Chairpersons Michael H. Malim, London, UK Julian Schulze zur Wiesch, Hamburg, Germany16:00 – 16:30 Keynote: HIV restriction - striking early

Michael H. Malim, London, UK

Hal

l F –

2.

Flo

or

16:30 – 16:45 Requirements for initiation factors in the translation of hepatitis C virusEsther Gonzalez-Almela, Madrid, Spain

16:45 – 17:00 Identifi cation of potent restriction factors of hepatitis C virus infection and their contribution to viral species-tropismRichard J. P. Brown, Hannover, Germany

17:00 – 17:15 Novel techniques for genome visualization reveal the fate of incoming adenoviral genomes against nuclear antiviral factorsTetsuro Komatsu, Bordeaux, France

17:15 – 17:30 The antiviral protein viperin targets tick-borne encephalitis virus replication and assemblyKirstin Vonderstein, Umeå, Sweden

17:30 – 17:45 In vivo evasion of MxA reveals pandemic potential of emerging infl uenza A virusesEbrahim Hassan, Freiburg, Germany

17:45 – 18:00 SMARCA2 the ATPase subunit of the chromatin remodeling BAF complex is required for the antiviral activity of MxAAlexandra Dudek, Freiburg, Germany

Detailed Programme

21

Wed

nesd

ay, 1

9th O

ctob

er

16

:00

– 1

8:0

0

WS3: Virus Attachment

and Entry

Chairpersons Dimitri Lavillette, Shanghai, China Urs Greber, Zurich, Switzerland

Hal

l A –

1.

Flo

or

16:00 – 16:30 Keynote: Insights into principles of virus entry and uncoatingUrs Greber, Zurich, Switzerland

16:30 – 16:45 Native structure of a retroviral envelope protein and its conformational change upon interaction with the target cellChristiane Riedel, Vienna, Austria

16:45 – 17:00 Quantitative phospho-proteomics reveal new insights into signaling events triggered by infl uenza A virus infectionSilke Stertz, Zurich, Switzerland

17:00 – 17:15 The cytoskeletal adaptor protein obscurin-like 1 interacts with L2 and is required for HPV16 endocytosisElena Wüstenhagen, Mainz, Germany

17:15 – 17:30 The spike protein of the middle east respiratory syndrome coronavirus has sialic acid binding activityIvy Widjaja, Utrecht, The Netherlands

17:30 – 17:45 Quantifi cation of the binding forces of Dengue virus with cell receptors at a single-virus levelYueh-Hsin Ping, Taiwan, Republic of China

17:45 – 18:00 Switching to LAMP1 during cell entry of Lassa virusRon Diskin, Rehovot, Israel

16

:00

– 1

8:0

0

WS4: Virus Replication

Strategies

Chairpersons Gabriella Campadelli-Fiume, Bologna, Italy Vincent Parissi, Bordeaux, France

Hal

l B –

1.

Flo

or

16:00 – 16:30 Keynote: Control of, and regulation by, the BKPyV miRNAMichael J. Imperiale, Ann Arbor MI, USA

16:30 – 16:45 An enterovirus mutant that can replicate in the absence of replication organellesFrank van Kuppeveld, Utrecht, The Netherlands

16:45 – 17:00 Chikungunya trans-replication systems as tools to study the properties of replicase proteinsTania Quirin, Helsinki, Finland

17:00 – 17:15 Delineating the interplay between the PB2 protein of infl uenza A virus and the host ubiquitin proteasome systemElise Biquand, Paris, France

17:15 – 17:30 Is replication fi delity of infl uenza A viruses modulated by a proofreading activity?Marion Declercq, Paris, France

17:30 – 17:45 Single-molecule FISH reveals non-selective packaging of Rift Valley fever virus genome segmentsPaul Wichgers Schreur, Lelystad, The Netherlands

17:45 – 18:00 Usp7, an ubiquitin specifi c protease, interacts with Merkel Cell polyomavirus large T-antigen and modulates viral DNA replicationManja Czech-Sioli, Hamburg, Germany

18:15 – 19:00 ESV Junior Investigator Award

Hal

l 1 –

2

. Fl

oo

r

18:00 – 20:00 Poster Session – Scientifi c Networking

22

6th European Congress of Virology

Thur

sday

, 20th

Oct

ober

08

:30

– 1

0:3

0

WS5: Adaptive Antiviral

Immunity and Viral Immune

Evasion

Chairpersons Thomas Harrer, Erlangen, Germany Julian Schulze zur Wiesch, Hamburg, Germany

Hal

l 1 –

2.

Flo

or

08:30 – 09:00 Keynote: Mechanisms of HIV pathogenesis and HIV cure – insights from the paediatric HIV infectionPhilip Goulder, Oxford, UK

09:00 – 09:15 Protein carbamoylation increases the restimulation of pp65-specifi c T cells in vitroRalf Wagner, Regensburg, Germany

09:15 – 09:30 Specifi city and phenotype of T cells in primary human cytomegalovirus infection in pregnancyDaniele Lilleri, Pavia, Italy

09:30 – 09:45 Sequence-function analysis of three T-cell receptors targeting the HIV-1 p17 epitope SLYNTVATLThomas Harrer, Erlangen, Germany

09:45 – 10:00 An immune-competent inbred mouse model of HCV-related rodent hepaci-virus infectionEva Billerbeck, New York City NY, USA

10:00 – 10:15 Identifi cation of novel MHC I and MHC II restricted hepatitis D virus-specifi c peptide epitopesJohanna Blöcker, Hamburg, Germany

10:15 – 10:30 Analysis of the adaptive cellular immune response to Nipah virus-like par-ticles in C57BL/6 and Balb/c miceSandra Diederich, Greifswald - Insel Riems, Germany

08

:30

– 1

0:3

0

WS6: Virus Maturation

and Egress

Chairpersons Hans-Georg Kräusslich, Heidelberg, Germany Beate Sodeik, Hannover, Germany

Hal

l F –

2.

Flo

or

08:30 – 09:00 Keynote: Herpesvirus nuclear egress – elucidation of the prototypic vesicular nucleo-cytoplasmic transportThomas Mettenleiter, Greifswald – Insel Riems, Germany

09:00 – 09:30 Keynote: Host-catalyzed capsid assembly modulation: A new approach to anti-viral drug discoveryVishwanath R. Lingappa, San Francisco CA, USA

09:30 – 09:45 A secretory pathway calcium ATPase regulates viral spread by modulating cellular proteolysisHans-Heinrich Hoffmann, New York City NY, USA

09:45 – 10:00 Incorporation of the infl uenza A virus NA segment does not require homo-logous non-coding sequencesSylvie van der Werf, Paris, France

10:00 – 10:15 Proteomics of HCV virions reveals a surprising role for the nucleoporin Nup98 in virus morphogenesisMaria Teresa Catanese, London, UK

10:15 – 10:30 Role of Rab33B and its autophagic Atg5/12/16L1 effector in hepatitis B virus morphogenesisChristina Bartusch, Mainz, Germany

08

:30

– 1

0:3

0

WS7: Advanced Virus

Diagnosis

Chairpersons Elisabeth Puchhammer, Vienna, Austria René A.A. van der Vlugt, Wageningen, The Netherlands

Hal

l A –

1.

Flo

or

08:30 – 09:00 Keynote: Prospects for digital PCR in viral diagnosticsWard De Spiegelaere, Ghent, Belgium

09:00 – 09:15 Infectious Laryngotracheitis virus (ILTV) vaccine intake evaluation by detec-tion of virus amplifi cation in feather pulps of vaccinated chickensIrit Davidson, Bet Dagan, Israel

09:15 – 09:30 Infl uence of glycoprotein C on Bovine Herpesvirus-1 virion composition and implications for diagnosticsSusanne Koethe, Greifswald - Insel Riems, Germany

09:30 – 09:45 The immunoglobulin-like domain of HsFcµR (TOSO, FAIM3) binds IgM/antigen immune complexes and can be used as a novel capture molecule in serological testsChristina Deschermeier, Hamburg, Germany

Detailed Programme

23

Thur

sday

, 20th

Oct

ober

WS7: Advanced Virus

Diagnosis

09:45 – 10:00 Development of ELISA for detection of Seneca Valley virus exposureZeynep Akkutay-Yoldar, Ankara, Turkey

Hal

l A –

1.

Flo

or

10:00 – 10:15 NS1-based anti-Zika virus ELISA revealed no cross-reactivity with other fl avi-virus infections or vaccinationKatja Steinhagen, Lübeck, Germany

10:15 – 10:30 Clinical evaluation of the Veris HCV assay for hepatitis C virus RNA quantifi -cationLaure Izquierdo, Villejuif, France

08

:30

– 1

0:3

0

WS8: Viral Patho-

genesis

Chairpersons Giorgio Palù, Padova, Italy Maria G. Masucci, Stockholm, Sweden

Hal

l B –

1.

Flo

or

08:30 – 09:00 Keynote: Viral interference with ubiquitin and UbL-regulated signaling pathwaysMaria G. Masucci, Stockholm, Sweden

09:00 – 09:15 Th17, CCR6+ cells lack RNAses and are highly permissive to HIV infection: Implications for pathogenesis and therapyAlfredo Garzino Demo, Padova, Italy

09:15 – 09:30 Bio-imaging of alphaviral disease in mice: A study using Ross River virusEssia Belarbi, Fontenay aux Roses, France

09:30 – 09:45 Comparative analysis between fl aviviruses reveals specifi c neural stem cell tropism for Zika virus in the mouse developing neocortexCecile Khou, Paris, France

09:45 – 10:00 Susceptibility and infl ammatory response of human neural cells to Zika virus and West Nile virus infectionGiovanna Desole, Padova, Italy

10:00 – 10:15 Transcriptome analysis of human fetal astrocytes infected with Zika virus reveals dysregulation of genes required for brain developmentDaniel Limonta, Edmonton, Canada

10:15 – 10:30 Pathogenesis of Zika virus infection in a non-human primate modelPatricia Pesavento, Davis CA, USA

10:30 – 11:00 Coffee Break Foyer D-G; Hall G, D and E - 2.Floor

11

:00

– 1

3:0

0

Plenary Session 2: Animal Models

for Virus Research

Chairpersons Marc Lütgehetmann, Hamburg, Germany Cesar Muñ oz-Fontela, Hamburg, Germany

Hal

l 1 –

2.

Flo

or11:00 – 11:30 Animal models to assess effi cacy of infectious disease intervention:

Ebola, CCHR and Infl uenzaMiles W. Carroll, Salisbury, UK

11:30 – 12:00 Human tumor virus infection and immune control in vivoChristian Münz, Zurich, Switzerland

12:00 – 12:30 Animal models of viral hepatitisAlexander Ploss, Princeton NJ, USA

12:30 – 13:00 Humanized mouse models for the study of viral pathogens and persistenceJ. Victor Garcia, Chapel Hill NC, USA

13:00 – 15:00 Lunch Break Foyer D-G; Hall G, D and E - 2.Floor

Satellite Symposium

13:15 – 14:15QIAGEN-Symposium:“Novel Technologies for Improved Pathogen Detection“

Hal

l F –

2

. Fl

oo

r

24

6th European Congress of Virology

Thur

sday

, 20th

Oct

ober

15

:00

–

17

:00

WS9: Humoral Immune Response to Viral

Infection

Chairpersons Florian Klein, Cologne, Germany Alexandra Trkola, Zurich, Switzerland

Hal

l 1 –

2.

Flo

or

15:00 – 15:30 Keynote: Virus, host and disease factors govern HIV-1 broadly neutralizing antibody inductionAlexandra Trkola, Zurich, Switzerland

15:30 – 15:45 Long-term immunogenicity of bivalent and quadrivalent human papillo-mavirus vaccines in the target population of organized vaccination programsLuisa Barzon, Padova, Italy

15:45 – 16:00 Association of human IgG1 heavy chain variants on neutralization capacity and antibody dependent cellular cytotoxicity against HCMVHannes Vietzen, Vienna, Austria

16:00 – 16:15 HIV Env antibody can provide sterilizing immunity in the strictest senseKlaus Überla, Erlangen, Germany

16:15 – 16:30 Hemagglutinin-stem nanoparticles generate heterosubtypic infl uenza protectionHadi Yassine, Doha, Qatar

16:30 – 16:45 Structural basis of Zika virus cross-reactivity and cross-neutralization with fl avivirus post-infection and post-vaccination seraKarin Stiasny, Vienna, Austria

16:45 – 17:00 Experimental infection of horses with nonprimate hepacivirus mediates immune protection against re-infectionStephanie Pfänder, Hannover, Germany

15

:00

– 1

7:0

0

WS10: Virus Structure and Imaging

Chairpersons Félix A. Rey, Paris, France Kay Grünewald, Hamburg, Germany

Hal

l F –

2.

Flo

or

15:00 – 15:30 Keynote: The structurally identifi ed homology between viral and cellular membrane fusion proteins highlights the impact of genetic exchanges during evolutionFélix A. Rey, Paris, France

15:30 – 15:45 Flying viruses – from biophysical to structural characterisationCharlotte Uetrecht, Hamburg, Germany

15:45 – 16:00 Live cell dynamics of herpesvirus nuclear egressJens Bosse, Hamburg, Germany

16:00 – 16:15 Cellular microtubule scaffold promotes effi cient assembly and genome packaging of the non-enveloped virus reovirusPranav Shah, Heidelberg, Germany

16:15 – 16:30 Aggregates or virus-like particles? Ordered structure of isolated matrix protein M1 revealed by SAXS and AFMEleonora Shtykova, Moscow, Russian Federation

16:30 – 16:45 Acidic pH-induced conformation and LAMP1 inding of the lassa virus glyco-protein spikeSai Li, Oxford, UK

16:45 – 17:00 Nucleic acid binding motif in capsid protein of Mason-Pfi zer monkey virusPavel Ulbrich, Prague, Czech Republic

15

:00

– 1

6:3

0

WS11: Approved Antivi-

ral Therapies

Chairpersons Hans-Jürgen Stellbrink, Hamburg, Germany Jürgen Rockstroh, Bonn, Germany

Hal

l A –

1.

Flo

or

15:00 – 15:30 Keynote: Approved antivirals for HIV, HBV and HCV: What has been achieved, what are the remaining challenges?Jürgen Rockstroh, Bonn, Germany

15:30 – 16:00 Keynote: Presence and future of HEV treatment optionsSven Pischke, Hamburg, Germany

16:00 – 16:15 Acute hepatitis E in patients with gynecological malignancy – a case seriesStefan Schlabe, Bonn, Germany

16:15 – 16:30 In silico evaluation of Oseltamivir treatment strategies against Infl uenza –Pneumococcus coinfectionAlessandro Boianelli, Braunschweig, Germany

Detailed Programme

25

Thur

sday

, 20th

Oct

ober

15

:00

– 1

7:0

0

WS12: Pediatric Viral

Infections

Chairpersons Dana Wolf, Jerusalem, Israel Annette Haberl, Frankfurt, Germany

Hal

l B –

1.

Flo

or

15:00 – 15:30 Keynote: Congenital human cytomegalovirus transmission and patho-genesis: From epidemiology to experimental modelingDana Wolf, Jerusalem, Israel

15:30 – 15:45 Differential diagnosis of respiratory and enteric viral infections in childrenAleksandra Nikonova, Moscow, Russian Federation

15:45 – 16:00 Discovery of a potent, M2-1-targeting inhibitor of human respiratory syncytial virus infection in vivoBenjamin Bailly, Gold Coast, Australia

16:00 – 16:15 Repurposing suramin and zanamivir into a synergistic combination that blocks human parainfl uenza type-3 virus infectionBenjamin Bailly, Gold Coast, Australia

16:15 – 16:30 Vaccine effectiveness and genetic diversity in the context of increasing immunization rates against Rotavirus infectionsCorinna Pietsch, Leipzig, Germany

16:30 – 16:45 Universal neonatal Cytomegalovirus screening using saliva: Report of an experience in an Italian centerSimona Fiorentini, Brescia, Italy

16:45 – 17:00 Development of a murine model of Enterovirus 71 (EV71) infection, disease, and pathology using mouse-cell-adapted strainsCarla B. L. Victorio, Singapore, Singapore

17:15 – 18:00 EVA – European Virology Award

Hal

l 1 –

2

. Fl

oo

r

17:30 – 19:30 Poster Session – Scientifi c Networking

from 18:30 ESV – Executive Board and Advisory Council Meeting

Hal

l C –

1.

Flo

or

26

6th European Congress of Virology

Frid

ay, 2

1st O

ctob

er

08

:30

– 1

0:3

0

WS13: Antiviral Vaccines

Chairpersons Ralf Wagner, Regensburg, Germany Giuseppe Pantaleo, Lausanne, Switzerland

Hal

l 1 –

2.

Flo

or

08:30 – 09:00 Keynote: HIV vaccine: Myth or reality?Giuseppe Pantaleo, Lausanne, Switzerland

09:00 – 09:15 rVSV-platform: Immunogenicity data against the vector and insert of rVSV-ZEBOV in healthy adults – a phase I studyChristine Dahlke, Hamburg, Germany

09:15 – 09:30 Vaccine generation against gamma herpesvirus infection in a murine surrogate modelBaila Samreen, Düsseldorf, Germany

09:30 – 09:45 Effi cient immunization and full protection from lethal challenge by DNA-YF-Vax, a novel thermostable and readily scalable plasmid-launched live-atten-uated yellow fever vaccine candidate produced in E. coliKai Dallmeier, Leuven, Belgium

09:45 – 10:00 Triterpen saponins of plant origin incorporated into saponin/lipid nano-particles as an effi cient adjuvant system for mucosal immunizationVladimir Berezin, Almaty, Kazakhstan

10:00 – 10:15 Modifi ed vaccinia virus based vaccine protection against MERS-CoV in fection in dromedary camelsV. Stalin Raj, Rotterdam, The Netherlands

10:15 – 10:30 Pathogens inactivated by low-energy-electron irradiation maintain antigenic properties and induce protective immune responsesJasmin Fertey, Leipzig, Germany

08

:30

– 1

0:3

0

WS14: Emerging Topics

in Veterinary Virology

Chairpersons Thomas Mettenleiter, Greifswald – Insel Riems, Germany Wim H. van der Poel, Wageningen, The Netherlands

Hal

l F –

2.

Flo

or

08:30 – 09:00 Keynote: Emerging topics at issue in veterinary virologyWim H. van der Poel, Wageningen, The Netherlands

09:00 – 09:15 Full-genome based molecular characterization of encephalitis-associated bovine astrovirusesTorsten Seuberlich, Bern, Switzerland

09:15 – 09:30 Newly discovered polyomaviruses in animals: Uncovering causalityPatricia Pesavento, Davis CA, USA

09:30 – 09:45 Macrophages from pigs lacking the SRCR5 domain of CD163 are resistant to porcine reproductive and respiratory syndrome virus infectionChristine Burkard, Roslin, UK

09:45 – 10:00 Virus-host interactome high-throughput mapping: From the identifi cation of new factors of pathogenicity and interspecies transmission to new thera-peutic targets for an animal arbovirusGrégory Caignard, Maisons-Alfort, France

10:00 – 10:15 Immunogenicity and protective effi cacy of recombinant Modifi ed Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens vaccineAsisa Volz, Munich, Germany

10:15 – 10:30 Novel variant of porcine epidemic diarrhea virus in England detected through archive miningFalko Steinbach, Addlestone, UK

08

:30

– 1

0:3

0

WS15: Oncogenic

Mechanisms of Viruses

Chairpersons Thomas Dobner, Hamburg, Germany Massimo Tommasino, Lyon, France

Hal

l A –

1.

Flo

or

08:30 – 09:00 Keynote: Novel insights into viral-mediated tumorigenesisSusanna Chiocca, Milano, Italy

09:00 – 09:30 Keynote: Oncogenic viruses and more: Impact on host pathways and co operation with environmental factorsMassimo Tommasino, Lyon, France

Detailed Programme

27

Frid

ay, 2

1st O

ctob

er

WS15: Oncogenic

Mechanisms of Viruses

09:30 – 09:45 Human papillomavirus oncogenes contribute to acquisition of stem cell ability in vitroKaterina Strati, Nicosia, Cyprus

Hal

l A –

1.

Flo

or

09:45 – 10:00 PTPN14 is a novel degradation target of human papillomavirus E7 onco-proteinAnita Szalmas, Debrecen, Hungary

10:00 – 10:15 Interaction of the Merkel Cell polyomavirus LT-antigen with host cell chromatinJuliane Theiss, Hamburg, Germany

10:15 – 10:30 Establishment of a human adult stem cell model to understand the role of EBV oncogenic mechanisms in epithelial malignanciesWilhelm Ching, Hamburg, Germany

08

:30

– 1

0:3

0

WS16: Viral Latency and

Persistence

Chairpersons Bernhard Fleckenstein, Erlangen, Germany Carmen Rivas, Madrid, Spain

Hal

l B –

1.

Flo

or

08:30 – 09:00 Keynote: Targeting of cellular SUMO-regulated pathways by KSHV latent protein LANA2Carmen Rivas, Madrid, Spain

09:00 – 09:15 Classical swine fever virus generate superinfection exclusion at the organism level in swineLlilianne Ganges, Barcelona, Spain

09:15 – 09:30 Parvovirus B19 persists in tonsillar B cellsMari Toppinen, Helsinki, Finland

09:30 – 09:45 Humanized mice to study acute and persistent human adenovirus infectionsEstefania Rodriguez, Hamburg, Germany

09:45 – 10:00 Generation of human peripheral neurons to study Varicella Zoster virus latency, reactivation and induction of painAbel Viejo-Borbolla, Hannover, Germany

10:00 – 10:15 Analyzing mechanisms of KSHV latency and intervention using novel in vitro and in vivo modelsTatyana Dubich, Braunschweig, Germany

10:15 – 10:30 BRD2/4-mediated chromatin association of LANA is important for latent persistence of KSHVRishikesh Lotke, Hannover, Germany

10:30 – 11:00 Coffee Break Foyer D-G; Hall G, D and E – 2.Floor

11

:00

– 1

3:0

0

Plenary Session 3: Emerging Virus

Infections

Chairpersons Marylyn M. Addo, Hamburg, Germany Denis Fargette, Montpellier, France

Hal

l 1 –

2.

Flo

or11:00 – 11:30 Filovirus infections in bats and humans

Jonathan Towner, Atlanta GA, USA11:30 – 12:00 Emerging viral infections: The power of deep sequencing

Martin Beer, Greifswald - Insel Riems, Germany12:00 – 12:30 Biogeography of viral emergence: Rice yellow mottle virus as a case study

Denis Fargette, Montpellier, France12:30 – 13:00 Emerging viruses in the Balkan and Mediterranean region

Anna Papa, Thessaloniki, Greece13:00 – 15:00 Lunch Break Foyer D-G; Hall G, D and E – 2.Floor

Satellite Symposium

13:15 – 14:45ANRS / DZIF Symposium: “HBV and HIV Cure“

Hal

l F –

2

. Fl

oo

r

28

6th European Congress of Virology

Frid

ay, 2

1st O

ctob

er

15

:00

– 1

7:0

0

WS17: Experimental

Antiviral Therapies

Chairpersons Ben Berkhout, Amsterdam, The Netherlands Ralf Bartenschlager, Heidelberg, Germany

Hal

l 1 –

2.

Flo

or

15:00 – 15:30 Keynote: From oncolytic virotherapy to oncolytic immunotherapyGabriella Campadelli-Fiume, Bologna, Italy

15:30 – 16:00 Keynote: Antiviral therapy of chronic hepatitis C: Remaining challenges and new opportunitiesRalf Bartenschlager, Heidelberg, Germany

16:00 – 16:15 Polo-like-kinase 1 is a proviral host-factor for hepatitis B virus replication and a target for combined antiviral strategiesDavid Durantel, Lyon, France

16:15 – 16:30 Characterization of a novel human monoclonal antibody targeting the hepatitis C virus envelope proteinAhmed Atef Mesalam, Ghent, Belgium

16:30 – 16:45 Humanization of a claudin-1-specifi c monoclonal antibody to prevent and cure HCV infection without escapeChe C. Colpitts, Strasbourg, France

16:45 – 17:00 A phase 1, open label, dose-escalation study of the safety, pharmacokinetics and antiretroviral activity of 10-1074 monoclonal antibody in HIV-infected and HIV-uninfected individualsTill Schoofs, New York City NY, USA

15

:00

– 1

7:0

0

WS18: Highly Pathogenic

Viruses

Chairpersons Stefan Günther, Hamburg, Germany Heinz Feldmann, Hamilton MT, USA

Hal

l F –

2.

Flo

or

15:00 – 15:30 Keynote: Vaccine approaches for highly pathogenic virusesHeinz Feldmann, Hamilton MT, USA

15:30 – 15:45 Interference of MERS-CoV accessory genes with the innate immune re sponse and their contribution to virulenceIsabel Sola, Madrid, Spain

15:45 – 16:00 Role of SARS-CoV viroporins E, 3a, and 8a in virus replication and virulence: Complementation between the PBMs of E and 3a proteinsCarlos Castaño-Rodríguez, Madrid, Spain

16:00 – 16:15 Immune markers of fatal human Ebola virus diseasePaula Ruibal, Hamburg, Germany

16:15 – 16:30 Regulation of Ebola virus matrix protein VP40 by SUMOMaite Baz-Martínez, Santiago de Compostela, Spain

16:30 – 16:45 Effi cacy of Favipiravir and Ribavirin in a novel mouse model of Lassa feverLisa Oestereich, Hamburg, Germany

16:45 – 17:00 HPAIV H5 evolution requires adaptation of the hemagglutinin by elevation of the fusion competence activation pHJürgen Stech, Greifswald – Insel Riems, Germany

15

:00

– 1

7:0

0

WS19: Viral Gene

Expression – Transcription,

Translation

Chairpersons Wolfram Brune, Hamburg, Germany Bryan R. Cullen, Durham NC, USA

Hal

l A –

1.

Flo

or

15:00 – 15:30 Keynote: Post-transcriptional regulation of viral gene expressionBryan R. Cullen, Durham NC, USA

15:30 – 15:45 A broad RNA virus survey identifi es the miR-17 family as a critical host factor for pestivirusesTroels K. H. Scheel, Copenhagen, Denmark

15:45 – 16:00 An unprecedented protein-stimulated -2/-1 ribosomal frameshift mechanism in arterivirusesEric Snijder, Leiden, The Netherlands

16:00 – 16:15 A systematic view on infl uenza induced host shut-offJulie Tai, Rehovot, Israel

16:15 – 16:30 Novel preferences in infl uenza A virus cap-snatchingZuleyma Peralta, New York City NY, USA

16:30 – 16:45 Spatiotemporal analysis of global protein synthesis and PML domains asso ciation during HSV infection revealed by click chemistrySu Hui Catherine Teo, London, UK

16:45 – 17:00 Cardiotonic steroids suppress adenovirus replicationMartha Brown, Toronto, Canada

Detailed Programme

29

Frid

ay, 2

1st O

ctob

er

15

:00

– 1

7:0

0

WS20: Viral Vectors for Vaccine Design

Chairpersons Gerd Sutter, Munich, Germany Peter Liljeström, Stockholm, Sweden

Hal

l B -

1.

Flo

or

15:00 – 15:30 Keynote: RNA replicon vaccinesPeter Liljeström, Stockholm, Sweden

15:30 – 15:45 Development of MVA-MERS-S for phase I clinical evaluation: A candidate vaccine against Middle East Respiratory Syndrome coronavirusAsisa Volz, Munich, Germany

15:45 – 16:00 Clonal Oka varicella vaccine variants with reduced viral genome size and presumed higher clinical safetyHusam Taher, Kiel, Germany

16:00 – 16:15 Development of an artifi cial reassortant of Infectious Salmon Anaemia Virus (ISAV) with reverse genetic system: The solution for a new vaccine against uncultivable HPR0 genotype strainsMarcelo Cortez-San Martín, Santiago de Chile, Chile

16:15 – 16:30 The viral vector vaccine VSV-GP as vaccine platformC. Anika Bresk, Innsbruck, Austria

16:30 – 16:45 Priming with a potent HIV-1 DNA vaccine frames the quality of T cell and antibody responses prior to a poxvirus and protein boostBenedikt Asbach, Regensburg, Germany

16:45 – 17:00 Integrative approaches towards the generation of a synthetic polio vaccineMohammad W. Bahar, Oxford, UK

17:15 – 19:00 General Assembly – ESV

Hal

l 1 –

2

. Fl

oo

r

17:15 – 19:00 Poster Session – Scientifi c Networking

19:00 – 00:00 Congress Dinner & Networking Event

Hal

l 3 –

G

roun

d

Flo

or

30

6th European Congress of Virology

Satu

rday

, 22nd

Oct

ober

08

:30

– 1

0:3

0

WS21: Viral Evolution and Resistance

Chairpersons Todd Allen, Cambridge MA, USA Rolf Kaiser, Cologne, Germany

Hal

l 1 –

2.

Flo

or

08:30 – 09:00 Keynote: HIV resistance testing from 1999 to 2016 and beyondRolf Kaiser, Cologne, Germany

09:00 – 09:15 Characterisation of longitudinal human cytomegalovirus genome diversity by next generation sequencing of blood samples from immunocompromised patients suggests turnover of viral strainsElias Hage, Hannover, Germany

09:15 – 09:30 PatchDetection: Inference of (seasonally) reoccurring patterns of patches under positive selection in human infl uenza A/H3N2 virusesThorsten R. Klingen, Braunschweig, Germany

09:30 – 09:45 Differences among mumps virus surface proteins between genotype G and other genotypes at sites important for immunity and pathogenesisTessa Vermeire, Ukkel, Belgium

09:45 – 10:00 Use of Ebola pseudoviruses to interrogate the impact of Ebolavirus gly coprotein evolution during the West African outbreakRichard A. Urbanowicz, Nottingham, UK

10:00 – 10:15 Fitness changes and mutation dynamics in evolved hepatitis C virus popu-lations in the cell culture systemElena Moreno del Olmo, Madrid, Spain

10:15 – 10:30 Ribavirin-induced mutagenesis of the hepatitis E virus genome in vivoDaniel Todt, Hannover, Germany

08

:30

– 1

0:3

0

WS22: Virus Epidemio-logy and Surveil-

lance

Chairpersons Marion Koopmans, Rotterdam, The Netherlands Christian Drosten, Bonn, Germany

Hal

l F –

2.

Flo

or

08:30 – 09:00 Keynote: MERS – a classical zoonosis with a pre-pandemic implicationChristian Drosten, Bonn, Germany

09:00 – 09:15 Seasonality and selective trends in viral acute respiratory tract infectionsPatrick Shaw Stewart, Hungerford, UK

09:15 – 09:30 Emergence of highly pathogenic H5Nx infl uenza A viruses is accompanied with a change in H5 receptor-binding specifi cityCornelis A.M. de Haan, Utrecht, The Netherlands

09:30 – 09:45 CCHFV in sub saharan africa – Where to fi nd and how to diagnose?Miriam Andrada Sas, Greifswald - Insel Riems, Germany

09:45 – 10:00 MERS update in Saudi Arabia and probable future outbreaksIslam Nour, Riyadh, Saudi Arabia

10:00 – 10:15 Epidemiology of the four human coronavirus 229E, HKU1, NL63, and OC43 detected over two years in hospitalized adult patientsSimona Fiorentini, Brescia, Italy

10:15 – 10:30 Targeted enrichment of viral DNA in soft tissues from 300-year-old mummies from LithuaniaKlaus Hedman, Helsinki, Finland

08

:30

– 1

0:3

0

WS23: Infection of the

Immuno-compromised

Chairpersons Thomas Schulz, Hannover, Germany Hans Hirsch, Basel, Switzerland

Hal

l A –

1.

Flo

or

08:30 – 09:00 Keynote: Immune responses in replicative and non-replicative virus patho-logy: What we can we learn from polyomavirusesHans Hirsch, Basel, Switzerland

09:00 – 09:15 The challenges of data robustness in sequencing complete human cyto-megalovirus genomes directly from clinical materialNicolas Suarez, Glasgow, UK

09:15 – 09:30 Are human myeloid dendritic cells hijacked by the BK polyomavirus?Mathieu Sikorski, Nantes, France

09:30 – 09:45 Role of neutralizing antibodies in the control of BK polyomavirus reactivation in kidney transplant recipientsDorian Mcilroy, Nantes, France

Detailed Programme

31

Satu

rday

, 22nd

Oct

ober

WS23: Infection of the

Immuno- compromised

09:45 – 10:00 Survival and immunological improvement of ART-naïve HIV patients by HPgV coinfectionGibran Horemheb-Rubio, Mexico City, Mexico

Hal

l A –

1.

Flo

or

10:00 – 10:15 Immune reconstitution hepatitis A in a patient with AIDS demonstrates the importance of immunopathologyThomas Harrer, Erlangen, Germany

10:15 – 10:30 Hepatitis E at a tertiary center in Northern GermanyDirk Westhölter, Hamburg, Germany

08

:30

– 1

0:3

0

WS24: Zoonotic Viruses

Chairpersons Gülsah Gabriel, Hamburg, Germany Noël Tordo, Paris, France

Hal

l B –

1.

Flo

or

08:30 – 09:00 Keynote: Ebola and Rabies, bats and dogs: Differences and similarities between two zoonoses, applicability of the “One Health“ conceptNoël Tordo, Paris, France

09:00 – 09:15 The sialic acid binding preference determines the differential interaction bet-ween infl uenza A viruses and streptococciJie Tong, Hannover, Germany

09:15 – 09:30 The neuraminidase protein of novel H7N9 virus displays reduced enzymatic activity resulting from mutation of the 2nd sialic acid binding siteMeiling Dai, Utrecht, The Netherlands

09:30 – 09:45 Host-symbionts interaction driving evolution of alpha and beta coronaviruses (CoVs) in their bat hostsStefania Leopardi, Legnaro, Italy

09:45 – 10:00 Bat coronaviruses in France and Western Palearctic: After MERS-CoV and SARS-CoV, are there other candidates to emergence?Meriadeg Ar Gouilh, Paris, France

10:00 – 10:15 Stem cell-derived hepatocellular systems for the study of genuine pan- genotype hepatitis E virus replicationViet Loan Dao Thi, New York City NY, USA

10:15 – 10:30 PTLV-1 among humans in two regions of tropical AfricaGrit Schubert, Berlin, Germany

10:30 – 11:00 Coffee Break Foyer D-G; Hall G, D and E – 2.Floor

11

:00

– 1

3:0

0

Plenary Session 4: Next Generation

Viromics

Chairpersons Adam Grundhoff, Hamburg, Germany Albert Osterhaus, Hannover, Germany

Hal

l 1 –

2.

Flo

or11:00 – 11:30 Virus genome variation in infected individuals and populations

Paul Kellam, Cambridge, UK

11:30 – 12:00 The merging of fi elds through NGS applications in emerging infectious diseases Marion Koopmans, Rotterdam, The Netherlands

12:00 – 12:30 Viral signatures of immune control of HIV and HCVTodd Allen, Cambridge MA, USA

12:30 – 13:00 Virus discovery in human and animals: From genomes to diseasesEric Delwart, San Francisco CA, USA

13:00 – 15:00 Lunch Break Foyer D-G; Hall G, D and E – 2.Floor

Satellite Symposium

13:15 – 14:45Erasmus MC / Institut Pasteur Symposium: “Emerging Zoonoses“

Hal

l A –

1

. Fl

oo

r

Satellite Symposium

13:15 – 14:45ESV – Symposium:”Challenges in Clinical Virology”

Hal

l F –

2

. Fl

oo

r

15

:00

– 1

7:0

0

WS25: Curative Strate-

gies for Virus Eradication

Chairpersons Ulrike C. Lange, Hamburg, Germany Thomas F. Baumert, Strasbourg, France

Hal

l 1 –

2

. Fl

oo

r

15:00 – 15:30 Keynote: Cell circuits of viral entry, disease biology and antiviral therapyThomas F. Baumert, Strasbourg, France

15:30 – 16:00 Keynote: Genome editing as antiviral therapyFrank Buchholz, Dresden, Germany

32

6th European Congress of Virology

Satu

rday

, 22nd

Oct

ober

WS25: Curative Strate-

gies for Virus Eradication

16:00 – 16:15 Novel targets for potent antiviral drugs: The development of Pritelivir and Letermovir against viruses from the herpes groupHelga Rübsamen-Schaeff, Frankfurt, Germany

Hal

l 1 –

2.

Flo

or

16:15 – 16:30 Natural humic substances interfere with multiple stages of the replication cycle of human immunodefi ciency virusYury Zhernov, Moscow, Russian Federation

16:30 – 16:45 Antiviral activity of apigenin against African swine fever virusHovakim Zakaryan, Yerevan, Armenia

15

:00

– 1

7:0

0

WS26: Virus Disco-

very, Typing and Metagenomics

Chairpersons Nicole Fischer, Hamburg, Germany Eric Delwart, San Francisco CA, USA

Hal

l F –

2.

Flo

or

15:00 – 15:30 Keynote: Animal viruses leaving the animal-human interfaceAlbert Osterhaus, Hannover, Germany

15:30 – 15:45 Polymycoviridae: An emerging family of mycovirusesIoly Kotta-Loizou, London, UK

15:45 – 16:00 Discovery and characterization of a new avian hepatitis B virus in a palaeo-gnath birdWendy K. Jo, Hannover, Germany

16:00 – 16:15 Co-circulation of potentially novel paramyxoviruses in bats in Central BrazilWilliam Marciel Souza, Ribeirão Preto, Brazil

16:15 – 16:30 Investigation of hantavirus prevalence in wild rodent population in the United KingdomJoe Chappell, Nottingham, UK

16:30 – 16:45 Sero- and genoepidemiology of two human protoparvoviruses, bufavirus and tusavirusElina Väisänen, Helsinki, Finland

16:45 – 17:00 HERV-W group evolutionary history: Characterization of the group in non-human primates and identifi cation of highly related sequences in new world monkeysNicole Grandi, Cagliari, Italy

15

:00

– 1

7:0

0

WS27: Vector Borne

Infections

Chairpersons Daniel Cadar, Hamburg, Germany Stéphane Blanc, Montpellier, France

Hal

l A –

1.

Flo

or

15:00 – 15:30 Keynote: Vector transmission: Commonalities and specifi cities in plant and animal virusesStéphane Blanc, Montpellier, France

15:30 – 16:00 Keynote: Zika virus pathogenesisHelen Lazear, Chapel Hill NC, USA

16:00 – 16:15 Interaction between fl aviviruses and alphaviruses during coinfection at the cell levelDimitri Lavillette, Shanghai, China

16:15 – 16:30 Mosquito saliva increases endothelial permeability in the skin, immune cell migration and dengue pathogenesis during antibody-dependent enhance-mentMichael A. Schmid, Berkeley CA, USA

16:30 – 16:45 Alpha-repeat molecules as novel antivirals against fl aviviruses by targeting the envelope glycoprotein and the NS1 proteinWilhelm Furnon, Lyon, France

16:45 – 17:00 Antiviral piRNA pathway in the arbovirus vector Aedes aegyptiMargus Varjak, Glasgow, UK

15

:00

– 1

7:0

0 WS28: Best of Posters

Chairpersons Julian Schulze zur Wiesch, Hamburg, Germany Karin Mölling, Berlin, Germany

Hal

l B –

1

. Fl

oo

r

15:00 – 17:00 Short presentations selected from Poster Sessions

17:15 – 18:00Life Science Nord – Poster Prize Farewell – Next Meeting Presentation

Hal

l 1 –

2

.Flo

or

Detailed Programme

33

Poster Exhibition and Poster Sessions

Scientifi c posters will be presented in the following topic groups:

There will be a Poster Session for each Poster Workshop. Please check the following pages for the specifi c date and time of the session.

Soft drinks and Pretzels will be offered during the Poster Sessions.

Immunity

WS 1, 2, 5, 9, 13, 20, 23 Hall E

Zoonoses, Emerging Infections

WS 14, 22, 24, 26, 27 Hall D

WS 18 Hall E

Basic Virology

WS 3, 4, 6, 8, 10, 15, 16, 19, 21 Foyer Hall D-G

Clinical Virology

WS 7, 11, 12, 17, 25 Hall E

34

6th European Congress of Virology

WS-1 Innate Antiviral Immu-nity and Viral Immune Evasion

19th Oct. 201618:00 – 20:00

Hall E

P1-2 Cytomegalovirus’ evasion from the peroxisome- dependent antiviral immune responseDaniela Ribeiro, University of Aveiro, Aveiro, Portugal

P1-3 Host factors interfering with early events of cytomega lovirus infection and viral gene expres-sion Ulfert Rand, Helmholtz Centre for Infection Research, Braunschweig, Germany

P1-4 Killer-cell immunoglobulin-like receptors and cytomega lovirus reactivation during late preg-nancy Diana Lorena Alvarado Hernández, Universidad Au-tónoma de San Luis Potosí, San Luis Potosi, Mexico

P1-5 Human Cytomegalovirus pp65 inhibits Interferon type I production through its interaction with the cGAS/STING axisSara Pautasso, University of Turin, Turin, Italy

P1-6 avb3-integrin cooperates with the IFN receptor signa ling and controls PD-L1 expressionTatiana Gianni, University of Bologna, Bologna, Italy

P1-7 KIR2DL2 activation by human Herpesviruses deter-mines viral escape to innate immunityRoberta Rizzo, University of Ferrara, Ferrara, Italy

P1-8 The innate response against oncolytic HSV retar-geted to cancer specifi c receptors Andrea Vannini, University of Bologna, Bologna, Italy

P1-9 Varicella zoster virus expresses a broad-range chemokine binding protein that enhances chemokine activity Víctor González Motos, Medizinische Hochschule Hannover (MHH), Hannover, Germany

P1-10 Infl uence of genotype A Hepatitis B virus envelope variability on HBs antigen (HBsAg) persistence in patients mono-infected or co-infected with human immun odefi ciency virus Hélène Jeulin, Université de Lorraine, Vandoeuvre-les-Nancy, France

P1-11 Cleavage of MAVS and interference with innate immune signaling is conserved among hepaciviral NS3/4A proteases Angga Kusuma, TWINCORE – Centre for Experi-mental and Clinical Infection Research, Hannover, Germany

P1-12 HLA-Bw4 80(T) and high HLA-Bw4 copy numbers in combination with KIR3DL1 are associated with superior immune control of HCV infection in peo-ple who inject drugs Jörg Timm, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany

P1-13 Peroxisomal MAVS is targeted by Hepatitis C virus NS3-4A to disrupt antiviral signalling response Ana Rita, Ferreira, University of Aveiro, Aveiro, Portugal

P1-14 Establishing robust induced pluripotent stem cell-derived model systems to study hepatitis C virus-host interactions Anja Schöbel, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

Poster Sessions

P1-15 Hepatitis E virus infection induces an innate im-mune response in human chimeric mice Lena Allweiss, Universitätsklinikum Eppendorf, Ham-burg, Germany

P1-16 Unphosphorylated ISGF3 drives constitutive transcription of interferon-stimulated genes and provides host antiviral defense Wenshi Wang, Erasmus MC, Rotterdam, Netherlands

P1-17 Reduced CD8+CD161+ MAIT cells in HCV and HIV/HCV co-infection Johanna Maria Eberhard, Universitätsklinikum Ep-pendorf, Hamburg, Germany

P1-18 Increased frequency of CD39+ CD56bright Natural Killer cells in HIV-1 infection correlates with im-mune activation and disease progression Patrick Dirks, Universitätsklinikum Eppendorf, Ham-burg, Germany

P1-19 The cellular transcription factor ZNF395 is involved in the control of HIV-1 replication in vivo and in vitro Gertrud Steger, Institute of Virology, Cologne, Germany

P1-21 Nuclear RIG-I exhibits antiviral activity against infl uenza virus Michaela Weber-Gerlach, Justus-Liebig University, Gießen, Germany

P1-22 Effect of Middle East Respiratory Syndrome Corona virus (MERS-CoV) Spike glycoprotein on macrophage innate immune response George Sourvinos, University of Crete, Heraklion, Greece

P1-23 Impact of host interferon-stimulated-gene-product 15 biodiversity on the deISGylase function of coronavirus Papain-like proteases Courtney Daczkowski, University of Georgia, Athens, United States

P1-24 Contribution of host and viral small non-coding RNAs to SARS-CoV lung pathology Lucia Morales, National Center of Biotechnology, Madrid, Spain

P1-25 Early endonuclease-mediated evasion of RNA sens-ing ensures effi cient coronavirus replication Eveline Patricia Kindler, Institute of Virology and Immuno logy, Bern, Switzerland

P1-26 The unfolded protein response is a prerequisite for Flavivirus-mediated interferon induction Alessandro Marcello, ICGEB, Trieste, Italy

P1-27 In vitro approach to study interactions of patho-genic and non-pathogenic hantaviruses with their natural and human hosts Myriam Ermonval, Institut Pasteur, Paris, France

P1-28 Genetic modifi cation of primary human airway epithelium – a platform for the study of respiratory viruses Hulda R. Jonsdottir, Institute of Virology and Immunology, Bern, Switzerland

P1-29 A comparative study of respiratory syncytial virus (RSV) infection of macrophage cell lines reveals remarkable differences in susceptibility Peter Delputte, University of Antwerp, Antwerpen, Belgium

35

P1-30 Biodiversity impact of host interferon-stimulated-gene-product 15 on the function of nairoviral deISGylases John Dzimianski, University of Georgia, Athens, United States

P1-31 Commensal bacteria-mediated IL-22 expression determines susceptibility of adult mice to Rota-virus infection Daniel Schnepf, Universitätsklinikum Freiburg, Freiburg im Breisgau, Germany

P1-32 IFN induction by rabies and other lyssaviruses: identi fi cation of critical residues in the viral phosphoprotein P Marco Wachowius, LMU Munich, Munich, Germany

P1-34 Differing substrate specifi city among PRRSV vOTUs, Scott Pegan, University of Georgia, Athens, United States

WS-2 Restriction Factors of Viral Infection

19th Oct. 201618:00 – 20:00

Hall E

P2-1 Murine cytomegalovirus M117 is an E2F regulator and functions as a host range determinant Eleonore Ostermann, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

P2-2 Regulatory interaction between the cellular restric-tion factor IFI16 and viral pp65 (pUL83) modulates viral gene expression and IFI16 protein stability Matteo Biolatti, University of Turin, Turin, Italy

P2-3 SamHD1 restricts human cytomegalovirus (HCMV) Ramona Businger, Institute of Medical Virology, Tübin-gen, Germany

P2-4 Merkel cell polyomavirus (MCPyV) replication is negatively regulated by the host restriction factor Kap1/TRIM28 Svenja Siebels, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

P2-5 Identifi cation of the nuclease involved in interfer-on-induced purging of HBV cccDNA Daniela Stadler, Technische Universität München / Helmholtz Zentrum München, Munich, Germany

P2-7 Analysis of APOBEC3G-mediated inhibition of Measles Virus replication Vishakha Tiwarekar, University of Würzburg, Würz-burg, Germany

P2-8 Tetherin counteraction by the Ebola virus glyco-protein Julia Nehls, Helmholtz Zentrum München – German Research Center for Environmental Health, Oberschleißheim, Germany

P2-9 SARS-CoV replication is down-regulated by p53 via interaction of the SARS-Unique Domain and PLpro with E3 ubiquitin ligase RCHY1Albrecht von Brunn, Max-von-Pettenkofer Institute/LMU München, München, Germany

P2-11 Interplay between the cellular restriction factor PML and dengue virus Federico Giovannoni, School of Sciences, University of Buenos Aires, Buenos Aires, Argentina

P2-12 Viperin biogenesis and antiviral effect against TBEV Arun Upadjyay, Umeå University, Umea, Sweden

P2-13 ARTD8 (PARP14) is involved in restriction of viral replication Matthias Liniger, Institute of Virology and Immunology (IVI), Federal Food Safety and Veterinary Offi ce and Vetsuisse Faculty, Mittelhäusern, Switzerland

P2-14 The antiviral potential of hypertonic response in Coxsackievirus infection: a novel direction for drug development Ye Qiu, University of British Columbia, Vancouver, Canada

P2-15 Control of Pepper mild mottle virus and Cucumber green mottle mosaic virus tobamoviruses collected in South Korea by Pseudomonas oleovorans Hyoun-Sub Lim, Chungnam National University, Daejeon, Korea, Republic of

WS-3 Virus Attachment and Entry

19th Oct. 201618:00 – 20:00

Foyer D-G

P3-1 Infection and replication effi ciency of different human cytomegalovirus glycoprotein O genotype mutants Julia Kalser, Medical University of Vienna, Vienna, Austria

P3-2 Confocal microscopy analysis reveals novel aspects of cell-to-cell spread of alphaherpesviruses Krystyna Bienkowska-Szewczyk, University of Gdansk, Gdansk, Poland

P3-3 Entry of herpes simplex virus 1 into human oral mucosa Dagmar Knebel-Mörsdorf, University of Cologne, Cologne, Germany

P3-4 Chimeric gB re-addresses HSV tropism to HER2 and bypasses the receptor-mediated activation of the upstream glycoproteins gD and gH Biljana Petrovic, University of Bologna, Bologna, Italy

P3-5 The Ephrin A2 receptor tyrosin kinase (EphA2) is downregulated by the KSHV immediate-early transactivator RTA Frank Neipel, Universitaetsklinikum Erlangen, Erlan-gen, Germany

P3-6 Analysis of the role of Nup153 in the stability of HBV Capsid under in vitro conditions mimicking the nuclear basket Lara Gallucci, UMR 5234 Microbiologie Fondamentale et Pathogénicité CNRS - University of Bordeaux, Bordeaux, France

P3-7 CD81 receptor regions outside the large extracel-lular loop determine hepatitis C virus susceptibility Gisa Gerold, Twincore, Center for Experimental and Clinical Infection Research, Hannover, Germany

P3-8 Retroviral envelope glycoprotein: key or picklock? David P ikryl, Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic

P3-9 G-Quadruplex-based approaches to inhibit the HIV-1 entry process Rosalba Perrone, University of Padua, Padua, Italy

P3-10 Morphological and functional changes in the well-differentiated airway epithelium after infection by infl uenza virus Nai-Huei Wu, University of Veterinary Medicine Han-nover, Hannover, Germany

P3-12 Receptor binding by H10N7 infl uenza viruses isolated from seals Jie Zhang, Francis Crick Institute Mill Hill Laboratory, London, United Kingdom

36

6th European Congress of Virology

P3-13 Studying Infl uenza A virus-receptor interactions using biolayer interferometryHongbo Guo, Utrecht University, Utrecht, Netherlands

P3-14 Distinct structural features of human enteric adenoviruses 40 and 41 as determinants affecting entry into host cells Martha Brown, University of Toronto, Toronto, Canada

P3-15 AMV248 open reading frame of Amsacta moorei entomopoxvirus (AMEV) encodes a glycosyl trans-ferase playing a role in virus attachment Zihni Demirbag, Karadeniz Technical University, Trabzon, Turkey

P3-17 Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during early stage infection Winke, Van der Gucht, University of Antwerp, Wilrijk, Belgium

P3-18 Elucidating autophagy-mediated-uncoating pro-cess of Dengue virus by single-virus FRET imaging Li-Wei Chu, National Yang-Ming University, Taipei, Taiwan, Republic of China

P3-19 Integrin avb3 is necessary for effi cient fl avivirus replication in mouse cell lines Vinicius Pinho dos Reis, Friedrich-Loeffl er-Institut, Greifswald - Insel Riems, Germany

P3-20 Receptor engagement of the porcine epidemic diarrhea virus Berend-Jan Bosch, Utrecht University, Utrecht, Netherlands

P3-21 Role of early steps of infection in the resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus Sebastien Felt, University of North Carolina at Char-lotte, Charlotte, United States

P3-22 Native mass spectrometry analysis of interactions between noroviruses and glycan mimetics Hao Yan, Heinrich-Pette-Institut, Hamburg, Germany

P3-23 Native mass spectrometry demonstrates the role of glycans in pathogen infection Julia Lockhauserbäumer, Heinrich Pette Institute, Hamburg, Germany

P3-24 Structural characterization of protein-lipid com-plexes involved in viral entry Johannes Heidemann, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

WS-4 Virus Replication Strategies

19th Oct. 201618:00 – 20:00

Foyer D-G

P4-2 UL11 is essential for equine herpesvirus 1 replica-tion in cell culture Yassien Badr, Gifu University, Gifu city, Japan

P4-3 Perilipin-2 regulates lipid droplet morphology and Hepatitis C Virus replication Susan Lassen, Heinrich Pette Institute, Hamburg, Germany

P4-4 Hepatitis C Virus infection perturbs the lipid profi le of the host cell Sarah Hofmann, Heinrich Pette Institute, Hamburg, Germany

P4-5 Hepatitis E virus replication and interferon re-sponse in human placental-derived cells Leonard Knegendorf, Institute for Experimental Virol-ogy, TWINCORE, Centre for Experimental and Clinical Infection Research; a joint venture between the Medi-cal School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany

P4-6 Replication properties among H9N2 avian infl u-enza viruses of Eurasian origin, Rokshana Parvin Bangladesh, Agricultural University, My-mensingh, Bangladesh

P4-7 Role of G6PD activity in regulating infl uenza virus replicationDonatella Amatore, University of Rome ‘Sapienza’, Rome, Italy

P4-8 Identifi cation of virus-host interactions at the coro-navirus replicative structures using a proximity-labelling approach Philip V’kovski, Institute of Virology and Immunology IVI, Bern, Switzerland

P4-9 Mutagenization of the MCPyV non coding control region (NCCR) to improve late gene expression Emma Kraus, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

P4-10 The ubiquitin proteasome system is necessary for effi cient human Astrovirus replication, Luis Alberto, Casorla-Pérez, National University of Mexico, Cuernavaca, Mexico

P4-11 Characterizing the role of the NS1-NS4B interac-tion for the Dengue virus life cycle Anna Płaszczyca, Heidelberg University, Heidelberg, Germany

P4-13 Nuclear localisation of West Nile virus non struc-tural protein 5 is crucial for viral replicationAdam Lopez-Denman, University of Melbourne / Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

P4-14 Genome-wide CRISPR/Cas9 screens to identify essential host factors for viral infectionsFriderike Weege, Max Planck Institute for Infection Biology, Berlin, Germany

WS-5 Adaptive Antiviral Immunity and Viral Immune Evasion

20th Oct. 201617:30 – 19:30

Hall E

P5-1 IFN-g 874 T/A polymorphisms in HBV patients in Khartoum State-SudanAbdelaziz Atta, Central Laboratory, Ministry of Higher Education and Scientifi c Research, Khartoum, Sudan

P5-2 HEV specifi c T-cell response in immunosuppressed and immunocompetent patients with acute or chronic hepatitis E Johanna Blöcker, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

P5-3 Analysis of HLA-C7-restricted CTL targeting a conserved epitope in HIV-1 Nef.Thomas Harrer, Universitätsklinikum Erlangen, Erlan-gen, Germany

P5-4 Antibody-induced internalization of the human respiratory syncytial virus fusion protein Annelies Leemans, University of Antwerp, Antwerp, Belgium

Poster Sessions

37

P5-5 Specifi cities and immunodominance of human CD4 T cell responses to the live-attenuated yellow fever vaccine Judith H. Aberle, Medical University of Vienna, Vienna, Austria

WS-6 Virus Maturation and Egress

20th Oct. 201617:30 – 19:30

Foyer D-G

P6-1 The presumed polyomavirus viroporin VP4 of SV40 or BKPyV is not required for viral progeny releaseChristine Hanssen Rinaldo, University Hospital of North Norway,Tromsø, Norway

P6-2 Herpes simplex membrane proteins gE/gI and US9 promote entry of virus particles into neuronal axons, initiating anterograde transport toward axon tips, by kinesin-1 motorsDavid Johnson, Oregon Health & Sciences University, Portland, United States

P6-3 RhoB GTPase is implicated in Herpes simplex virus type-1 (HSV-1) infection George Sourvinos, University of Crete, Heraklion, Greece

P6-4 Cellular localization of UL11 protein in equine herpesvirus 1 infected cellsYassien Badr, Gifu University, Gifu city, Japan

P6-5 Identifi cation of the ATP-binding site in the heli-case subunit pUL105 of human cytomegalovirus GAETAN Ligat, Univ. Limoges, UMR 1092, Limoges, France

P6-6 Hepatitis C virus is released via a non-canonical secretory route Linda Wiltzer-Bach, University Clinic Tübingen, Tübingen, Germany

P6-7 Extracellular maturation of secreted hepatitis C virus particles by incorporation of Apoliporotein E enhances infectivity and partially protects from neutralizing antibodiesDorothea Bankwitz, TWINCORE, Centre for Experi-mental and Clinical Infection Research; a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI), Hannover, Germany

P6-8 Quantitative lipid droplet proteome analysis iden-tifi es Annexin A3 as a cofactor for HCV particle production Kathrin Rösch, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

P6-9 Novel stem cell-derived polarized hepatocel-lular systems for the studies of hepatitis E virus secretion Viet Loan, Dao Thi, Rockefeller University, New York City, United States

P6-10 Involvement of AIP1/Alix in the Feline Immunodefi -ciency Virus egress from infected cells Arianna Calistri, University of Padova, Padova, Italy

P6-11 Elucidating the composition of a “transport of p8 complex” (TOPC) to understand transfer of HTLV-1 p8 to target cells Andrea K. Thoma-Kress, Institute of Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

P6-12 The hemagglutinin of a H5N1 highly pathogenic avian infl uenza virus exhibits a high pH threshold of fusion but does not rely on the ion channel protein M2 for maturation Gert Zimmer, Institute of Virology and Immunology (IVI), Federal Food Safety and Veterinary Offi ce and Vetsuisse Faculty, Mittelhäusern/Bern, Switzerland

P6-13 Membrane budding regulated by a critical residue located at the putative dimeric interface of the canine distemper virus matrix protein Fanny Bringolf, University of Bern, Vetsuisse Faculty, Bern, Switzerland

P6-14 Dengue viruses are egressed in extracellular vesicles Chih-Ling Liu, National Yang-Ming University, Taipei, Taiwan, Republic of China

P6-15 Monitoring physiological changes of a haloarchae-on during the exit of virusesJulija Svirskaite, University of Helsinki, Helsinki, Finland

WS-7 Advanced Virus Diagnosis

20th Oct. 201617:30 – 19:30

Hall E

P7-1 Introduction of self-sampling for Human Papillo-mavirus-DNA detection in Cochabamba, Bolivia: A preliminary study of compliance and feasibilityPedro Surriabre, Universidad Mayor de San Simon, Cochabamba, Bolivia

P7-2 Detection and quantifi cation of infectious adeno-viruses in the early stages of infection – ICC-qPCR versus immunolabeling Mihayl Varbanov, Université de Lorraine, Nancy, France

P7-3 Validation of the RealStar® Orthopoxvirus PCR Kit 1.0 for detection of Orthopoxvirus and differentia-tion of variola virus Stephan Ölschläger, altona Diagnostics GmbH, Hamburg, Germany

P7-4 Microsphere-based IgG avidity assays using as model human Parvovirus B19 and CMVYilin Wang, University of Helsinki, Helsinki, Finland

P7-5 Diagnostic value of pathogen specifi c antibody coeffi cients in uveitis patients Mario Hönemann, Institute of Virology, Leipzig Univer-sity, Leipzig, Germany

P7-6 Evaluation of the performance of four Herpes Simplex Virus (HSV) immunofl uorescence assay (IFA) slides for the detection of HSV IgMJudith Chui Ching Wong, Singapore General Hospi-tal, Singapore, Singapore

P7-7 Discrepancy of anti-HEV test results determined by different seroassaysWerner Dammermann, University Medical Center Brandenburg, Brandenburg an der Havel, Germany

P7-8 Expression of recombinant Mouse Hepatitis Virus proteins in Escherichia coli for the improvement of diagnostic assays Julia Nickolaus, Leipzig University, Faculty of Veteri-nary Medicine, Leipzig, Germany

P7-10 Evaluation of RealStar RT-PCR kits for fi lovirus detection in the laboratory and fi eld Toni Rieger, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

38

6th European Congress of Virology

P7-11 Evaluation of a real-time RT-PCR kit for detection of Lassa virus Stephan Ölschläger, altona Diagnostics GmbH, Hamburg, Germany

P7-12 Development and validation of a sensitive and specifi c real-time RT-PCR system for the qualitative detection of Enterovirus and Rhinovirus RNA Mareen Zaruba, altona Diagnostics GmbH, Hamburg, Germany

P7-13 Validation of the RealStar® Dengue Type RT-PCR Kit 1.0 for differentiation of dengue virus types 1-4 Stephan Ölschläger, altona Diagnostics GmbH, Hamburg, Germany

P7-14 Universal primers to detect emerging Reptar-naviruses Hasan Alrashedi, University of Reading, Reading, United Kingdom

P7-15 The production of monoclonal antibodies against pestiviral immunogenic proteins for diagnostic purpose Tuba Cigdem Oguzoglu, Ankara University Veterinary Faculty, Ankara, Turkey

P7-17 Screening of nasal swabs from patients from Casablanca (Morocco) with respiratory symptoms of unknown etiologyJanine Michel, Robert Koch Institute, Berlin, Germany

P7-18 Plaque assay optimization of the Newcastle disease virus in chicken embryo fi broblast cell line (DF1) Ray Izquierdo-Lara, Farvet S.A.C, Chincha Alta, Peru

P7-20 Cell-based biosensors for detection and quanti-fi cation of label-free virus and viral vectors for research and diagnostics Miguel Ricardo Guerreiro, iBET – Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal

WS-8 Viral Pathogenesis20th Oct. 201617:30 – 19:30

Foyer D-G

P8-1 Human papillomavirus infection – a possible cause of spontaneous abortion and spontaneous preterm delivery Lea Maria Margareta Ambühl, North Denmark Re-gional Hospital/Aalborg University, Hjørring, Denmark

P8-2 Merkel cell polyomavirus T antigens upregulate IL17F activity in Merkel cell carcinomaKashif Rasheed, University of Tromsø, Tromsø, Norway

P8-3 Analysis of the molecular mechanisms underlyning the different susceptibility of breast adenocarci-noma derived cell lines to g-34.5 deleted herpes simplex virus type 1 replicationAdriana Vitiello, University of Padova, Padova, Italy

P8-4 Role of pattern recognition receptors in the patho-genesis of Herpes simplex virus -1 induced uveitis in a rabbit animal model Archit Kumar, PGIMER, Chandigarh, India

P8-5 Infectivity and cytopathogenicity after infection with herpes simplex virus type 1 or 2 during differ-entiation to human cortical neurons from induced pluripotent stem cells Tomas Bergström, University of Gothenburg, Gothen-burg, Sweden

P8-6 Interaction of the HSV-2 regulator protein ICP0 with the cellular E3 ubiquitin ligase SIAH-1 Julia Czechowicz, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

P8-7 Is HHV-6A associated to female infertility?Dario Di Luca, University of Ferrara, Ferrara, Italy

P8-8 Effect of equine herpesvirus type 1 (EHV-1) infec-tion of nasal mucosa epithelial cells on different elements of the extracellular matrix Hossein Bannazadeh Baghi, Infectious and Tropical Diseases Research Center,Tabriz University of Medical Sciences, Tabriz, Iran, Islamic Republic of

P8-9 Hepatic microRNA expression levels are associated with clinical parameters in Russian patients with chronic hepatitis C Tatyana Viktorovna Vishnevskaya, N.F Gamaleya Federal Research Center for Epidemiology and Micro-biology, Moscow, Russian Federation

P8-10 Membranoproliferative glomerulonephritis associ-ated with an HIV infection Hicham Rafi k, Military Hospital, Rabat, Morocco

P8-11 Contribution of gag, pol and env regions to overall viral replicative fi tness of HIV-1 from patients without antiretroviral therapyLenka Sácká, Institute of Organic Chemistry and Biochemistry ASCR, Prague, Czech Republic

P8-12 The omega-3 docosahexaenoic acid boosts HIV-1 infectivity in ex vivo treated CD4+ T cells Olivia Tort, IDIBAPS / Hospital Clínic, Barcelona, Spain

P8-13 Reovirus infection alters host cell alternative splic-ing landscapeSimon Boudreault, Université de Sherbrooke, Sher-brooke, Canada

P8-14 HMGB1 is a potential biomarker for severe viral hemorrhagic fevers Misa Korva, University of Ljubljana, Faculty of Medi-cine, Ljubljana, Slovenia

P8-15 Chimeric mice with competent hematopoietic Immunity reproduce key features of severe Lassa fever Lisa Oestereich, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

P8-16 Mechanisms underlying the neuropathogenesis of Rabies virusChloe Scordel, Ludwig-Maximilians-University Munich, Munich, Germany

P8-17 Interactions of Pseudorabies virus with porcine maxillary nerve Konstantinos Papageorgiou, Aristotle University of Thessaloniki, Thessaloniki, Greece

P8-18 Schmallenberg virus incursion into Great Britain: identifi cation of mutations and a large deletion in the M segment of British fi eld samples that result in attenuation of SBV Falko Steinbach, APHA, Addlestone, United Kingdom

P8-20 A mutation in the membrane protein strongly af-fects pathogenesis of West Nile FlavivirusNathalie Pardigon, Institut Pasteur, Paris, France

P8-21 Type I Interferon response in olfactory bulb, the site of tick-borne fl avivirus accumulation, is primar-ily regulated by IPS-1Chaitanya Kurhade, Molecular Infection Medicine, Sweden (MIMS), Umea University, Umea, Sweden

P8-22 Classical swine fever virus and African swine fever virus interaction in experimentally infected wild boars Sara Muñoz-González, IRTA, Barcelona, Spain

Poster Sessions

39

P8-23 Two Isolates of Turnip mosaic virus show symptom differences in N. benthamiana, Raphanus sativus and Brassica rapa determined by the P3 protein Hyoun-Sub Lim, Chungnam National University, Daejeon, Korea, Republic of

P8-24 Identifi cation and characterization of Sugarcane mosaic virus causing Maize lethal necrotic disease in Kenya Henry Ondabu, University of Nairobi, Nairobi, Kenya

P8-25 The Plum pox virus 6K1 protein is required for viral replication and targets the viral replication complex at the early infection stage Aiming Wang, Agriculture and Agri-Food Canada, London, Canada

P8-26 Characteriztion of maize chlorotic mottle virus causing maize lethal necrosis disease in Kenya Nickson Sananka, University of Nairobi, Nairobi, Kenya

WS-9 Humoral Immune Response to Viral Infection

20th Oct. 201617:30 – 19:30

Hall E

P9-1 Production and characterization of monoclonal antibodies against yeast-expressed hepatitis E virus capsid proteins Martynas Simanavicius, Institute of Biotechnology of Vilnius University, Vilnius, Lithuania

P9-2 Isolation and characterization of human memory B-cell antibodies against Chikungunya virus Oxana Vratskikh, Institut Pasteur, Paris, France

P9-3 Serological assessment of the role of rodents as potential secondary reservoir during the West-African outbreak of the years 2014-2016 Susanne M. Köhler, Robert Koch Institute, Berlin, Germany

WS-10 Virus Structure and Imaging

20th Oct. 201617:30 – 19:30

Foyer D-G

P10-1 Real-time viral particle quantifi cation and sizing: How biophysics supports virology Aure Saulnier, Sanofi Pasteur, Marcy l’Etoile, France

P10-2 Amphipathic secondary structure elements and putative cholesterol binding domains (CRAC’s) as governing factors of high-specifi c matrix protein interactions with raft-type membrane in the enveloped viruses Victor Radyukhin, MV Lomonosov Moscow State University,A.N. Belozersky Institute of Physico-Chemi-cal Biology, Moscow, Russian Federation

P10-3 Investigation of the full-length nuclear export protein (NEP) of the infl uenza A virus in solution by small-angle X-ray scattering Victor Radyukhin, A.N. Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russian Federation

P10-4 Potyvirus Potato Virus A coat protein posses unu-sual properties and forms short virus-like particles Alexander Ksenofontov, A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russian Federation

P10-5 Cryo-EM structure of a new internal membrane ss-DNA-bacteriophage found in a boreal lakeLuigi De Colibus, University of Oxford, Oxford, United Kingdom

WS-11 Approved Antiviral Therapies

20th Oct. 201617:30 – 19:30

Hall E

P11-2 Predication of sofosbuvir response using a single nucleotide polymorphism of interferon lambda-4 gene as a predictive factorAmal Saafan, Beni-Suef, Beni-Suef, Egypt

WS-12 Pediatric Viral Infections

20th Oct. 201617:30 – 19:30

Hall E

P12-1 Epidemiology and clinical features of parechovirus infection among young children in Hong Kong Paul Chan, Chinese University of Hong Kong, Hong Kong SAR, China

P12-3 Fast evaluation of hens and mouse anti-rotavirus A antibodies neutralization activity by developed real-time PCR-based protocolAleksandra Nikonova, Mechnikov Research Institute for Vaccines and Sera, Moscow, Russian Federation

P12-4 Detection and characterization of group C rotavi-rus in children in IndiaVasundhara Razdan Tiku, All India Institute of Medical Sciences (AIIMS)India, New Delhi, India

P12-5 Viral etiology and characteristics of acute respira-tory infections in hospitalized children in Zagreb region, Croatia Suncanica Ljubin-Sternak, School of Medicine, Univer-sity of Zagreb, Zagreb, Croatia

WS-13 Antiviral Vaccines21th Oct. 2016 17:15 – 19:00

Hall E

P13-1 Establishment of the 3rd national reference stand-ard for varicella vaccine in Korea Seokkee Chang, National Institute of Food and Drug Safety Evaluation, Cheongju-si, Korea, Republic of

P13-3 FcgR-mediated phagocytosis by broadly protective infl uenza A virus IgGs Annasaheb Kolpe, Medical Biotechnology Center, VIB, Ghent, Belgium

P13-4 Vaccination with Chimeric Newcastle Disease virus (NDV) improves protection after homologous challenge: The importance of cytoplasmatic tails in viral replication and protection Ray Izquierdo-Lara, FARVET SAC, Chincha Alta, Peru

P13-5 Towards pre-defi ned rules for targeted viral genome re-encoding as a potential means of developing live-attenuated virus vaccinesRaphaëlle Klitting, Aix-Marseille Univ - Institut de Re-cherche pour le Développement - Ecole des Hautes Etudes en Santé Publique, Marseille Cedex, France

P13-6 Generation of Porcine Reproductive and Respira-tory Syndrome (PRRS) virus-like-particles (VLPs) with different protein composition Marga Garcia Duran, INGENASA, Madrid, Spain

P13-7 Double-stranded RNA molecules for TMV p126 and CP genes, when applied exogenously, they induce resistance against TMV in tobacco Naga Charan Konakalla, Agricultural University of Athens, Athens, Greece

P13-8 Corynebacterium cutis lysate treatment can changes the effi cacies of PPR vaccineIRMAK Dik, University of Selcuk /Faculty of Veterinary Medicine, Konya, Turkey

40

6th European Congress of Virology

WS-14 Emerging Topics in Veterinary Virology

21th Oct. 201617:15 – 19:00

Hall D

P14-1 The genetic diversity of bovine papillomaviruses from different papillomatosis cases in Turkish cattle Seval Bilge Da alp, Ankara University Faculty of Veterinary Medicine, Ankara, Turkey

P14-2 Applicability of contact sentinel mice for the detection of common viral pathogens in laboratory mouse husbandry Antje Rueckner, Leipzig University, Faculty of Veterinary Medicine, Leipzig, Germany

P14-3 Reticuloendotheliosis virus (REV): Did it already arrive in Brazil?Giovana Santos Caleiro, Institute of Tropical Medicine of São Paulo, São Paulo, Brazil

P14-4 Expression of p53 protein, Jaagsiekte sheep retro-virus matrix protein, and surfactant protein in the lungs of sheep with pulmonary adenomatosisSevil Atalay Vural, Ankara University Faculty of Veteri-nary Medicine, Ankara, Turkey

P14-5 A phylogenetic analysis of non-cytopathogenic Bovine viral Diarhhea virus isolates from heifers with respiratory diseaseHarun Albayrak, Ondokuz Mayis University, Samsun, Turkey

P14-7 Porcine atypical pestiviruses in Austria Christiane Riedel, Vetmeduni Vienna, Vienna, Austria

P14-9 Development of tools for diagnosis and prevention of Nodavirus outbreaks Carmen Galán, INGENASA, Madrid, Spain

P14-10 Real-time PCR SYBR® Green-based detection assay for rapid screening and surveillance of Bornavirus Marlene Cavaleiro Pinto, Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal

P14-12 Serologic signs of three important viral respiratory diseases of in various ruminants in small-sized enterprises, Turkey Harun Albayrak, Ondokuz Mayis University, Samsun, Turkey

P14-13 Application of Rift Valley fever virus vaccines for camelids – safety, immunogenicity and pathogenic-ity of MP-12 vaccination of alpacas Melanie Rissmann, Friedrich-Loeffl er-Institut, Greif-swald, Germany

P14-14 Differential interaction of gC1qR protein with the capsid proteins of porcine circoviruses Kouokam Fotso Guy Baudry, ANSES Ploufragan/Plou-zané, Ploufragan, France

P14-15 A comparison of virus concentration methods for molecular detection of infectious pancreatic necrosis virus (IPNV) Harun Albayrak, Ondokuz Mayis University, Samsun, Turkey

P14-16 Clinical and necropsy fi ndings of viral nervous and necrosis (VNN) in European seabass (Dicentrarchus labrax) Harun Albayrak, Ondokuz Mayis University, Samsun, Turkey

WS-15 Oncogenic Mecha-nisms of Viruses

21th Oct. 201617:15 – 19:00

Foyer D-G

P15-1 Viruses associated with female breast cancerFarbod Alinezhad, Faculty of Medicine, Urima University of Medical Sciences, Urmia, Iran, Islamic Republic of

P15-2 The ORF012 gene of the oncogenic Marek’s disease virus type 1 encodes a novel SR-like phos-phoprotein essential for virus growth Timo Schippers, Freie Universität Berlin, Berlin, Germany

P15-3 Prevalence and characteristics of Epstein-Barr virus-associated gastric carcinomas in the centre of Portugal Célia Nogueira, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

P15-4 Role of HIV matrix protein p17 variants in lym-phoma pathogenesis Arnaldo Caruso, University of Brescia Medical School, Brescia, Italy

P15-5 The HTLV-1 oncoprotein Tax impacts Collagen type IV a1 and a2 (COL4A1 and COL4A2) in order to maintain a transformed phenotype of tumor cells Sebastian Millen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany

P15-6 The VEGF/VEGFR pathway implicated in angio-genesis is deregulated in lung cancers induced by JSRV Maryline Gomes, UMR754 - INRA/Université Lyon 1, Lyon, France

P15-7 Role of SUMO in the modulation of the PI3K/AKT pathway by infl uenza A virus NS1 proteinAhmed El Motiam, CIMUS/ Santiago de Compostela, Santiago de Compostela, Spain

WS-16 Viral Latency and Persistence

21th Oct. 201617:15 – 19:00

Foyer D-G

P16-1 Human cytomegalovirus latent genome mainte-nance Daniela Pothmann, University of Regensburg, Regensburg, Germany

P16-2 Thyroid gland as the site of human herpes virus 6 persistence in patients with autoimmune thyroiditis Maksims Cistjakovs, RSU A.Kirchenstein Institute of Microbiology and Virology, Riga, Latvia

P16-3 HHV-6 and HHV-7 associated changes in the frontal and temporal lobes of the brain of elderly subjects Sandra Skuja, Riga Stradins University, Riga, Latvia

P16-4 Possible involvement of HHV-6 and HHV-7 infec-tion in rheumatoid arthritis and osteoarthritis development Zaiga Nora-Krukle, Riga Stradins University, Riga, Latvia

P16-5 A comparative epigenome and transcriptome analysis of KSHV and MHV68 latency Thomas Günther, Heinrich-Pette-Institute, Leibniz In-stitute for Experimental Virology, Hamburg, Germany

P16-6 Complex quantifi cation of the HIV reservoir in different CD4+ subsets including regulatory T-cells using a novel Droplet Digital PCR based approach Gabor Artur Dunay, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

P16-7 Kinetics of HIV-1 latency reversal and HIV-1 infec-tion measured by a novel fl ow-based technique Gloria Martrus, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

Poster Sessions

41

P16-8 Targeted HIV-1 latency reversal using CRISPR/Cas9-derived transcriptional activator systems Julia K. Bialek, Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany

P16-9 The pestiviral IFN antagonist Erns cleaves dsRNA as nicking endoribonucleaseCarmela Lussi, Institute of Virology and Immunology (IVI), Federal Food Safety and Veterinary Offi ce and Vetsuisse Faculty, Bern, Switzerland

P16-10 In vitro evolution of persistent rabies virus: a role for IFN induction?Alexander Ghanem, LMU Munich, München, Germany

WS-17 Experimental Antivi-ral Therapies

21th Oct. 201617:15 – 19:00

Hall E

P17-1 Modeling of human papillomavirus infection in vitro: the infl uence of Protefl azid on the papilloma-virus reproduction Darya Starosyla, L.V. Gromashevskiy Institute of Epidemiology and Infectious Diseases NAMSU, Kyiv, Ukraine

P17-2 Antiviral activity of curcumin associated to nanoe-mulsions in HPV-16 E6 positive vulva cell lines Caroline Measso Bonfi m Azol, Unesp, Sao Jose do Rio Preto, Brazil

P17-4 Induction of transcription from the LCR of HPV-16 by HDACi opposed by host-cell differentiation and episomal DNA maintenance Ekaterina Bojilova Albert, Université Libre de Brux-elles, Brussels, Belgium

P17-5 Targeting the highly-conserved a2-helix of HPV E6 oncoprotein: a new strategy for the development of anticancer drugsLorenzo Messa, University of Padova, Padova, Italy

P17-7 Use of multiplex real-time PCR assay for cell-culture based testing of antiviral compounds with potential activity against human adenovirus CTomasz Dzieciatkowski, Medical University of Warsaw, Warsaw, Poland

P17-8 Inhibition of human Cytomegalovirus infection by the CRIPSR/Cas9 systemJanina Gergen, INSERM, Nantes, France

P17-9 Identifi cation of small molecules inhibiting the dimerization of HCMV DNA polymerase processiv-ity factor UL44Veronica Di Antonio, University of Padova, Padova, Italy

P17-10 Antiviral activity of cerium dioxide nanoparticles in A-549 (lung human carcinoma) cell lineOlga Shydlovska, National Academy of Sciences of Ukraine, D. K. Zabolotny Institute of Microbiology and Virology, Kyiv, Ukraine

P17-11 Retinoblastoma cells are susceptible to terminase inhibitorsElke Bogner, Charité – Universitätsmedizin Berlin, Berlin, Germany

P17-12 Tetrahologenated benzimidazole D-ribonucleo-sides are active against Rat Cytomegalovirus in 2-D as well as 3-D environment Elke Bogner, Charité – Universitätsmedizin Berlin, Berlin, Germany

P17-13 G-Quadruplex mediated anti-HSV-1 activity of a core extended Napthalene Diimide compound Sara Callegaro, University of Padova, Padua, Italy

P17-14 Gene therapy of AIDS: a novel approach combin-ing anti HIV-1 siRNAs and a fusion inhibitor Arianna Calistri, University of Padova, Padova, Italy

P17-15 Presence, function and targeting of G-quadruplex-es in the HIV-1 LTR promoter Sara Richter, University of Padua, Padua, Italy

P17-16 Evaluation of anti infl uenza virus activity of Pega-numharmala L. seed extract in MDCK cell lineAli Karimi, Shahrekord University of Medical Sciences, Shahrekord, Iran, Islamic Republic of

P17-17 Identifi cation of novel nucleoside analogues that inhibit coronavirus replicationNatacha Ogando, Leiden University Medical Center, Leiden, Netherlands

P17-18 Co-culture of endothelial cells and monocytes as a potential model to study dengue pathogenesis and screen compounds with therapeutic potentialFrancielle Tramontini Gomes de Sousa Cardozo, University of Sao Paulo, Sao Paulo, Brazil

P17-19 Combined application of antivirals against Cox-sackievirus B3 infections in newborn miceAdelina Stoyanova, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofi a, Bulgaria

P17-21 AR-12, a novel host cell directed broad spectrum antiviral drug provides a survival benefi t in the rabbit hemorrhagic fever modelStefan Proniuk, Arno Therapeutics, Flemington, United States

P17-22 Squalamine – evaluation of antiviral properties of aminosterols from sharksMihayl Varbanov, Université de Lorraine, Nancy, France

P17-23 Antiviral activity of extracts isolated from Portu-guese plantsCélia Nogueira, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

WS-18 Highly Pathogenic Viruses

21th Oct. 201617:15 – 19:00

Hall E

P18-1 Longitudinal study on persistence and clearance of Ebola virus RNA from seminal fl uid of Ebola virus disease survivors Stephan Günther, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

P18-2 Ebola disease in Mauritian Cynomolgus macaques: Establishment of a model and analysis of virus populationsGéraldine Piorkowski, UMR ‘Emergence des Patholo-gies Virales’ (EPV: Aix-Marseille University - IRD 190 – Inserm 1207 – EHESP – IHU Méditerranée Infection), Marseille, France

P18-3 Functional and structural analysis of Andes Virus L protein N-terminal domain, a potential pharmaco-logical targetYaiza Fernandez-Garcia, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany

P18-4 Screening of vector populations for different arboviruses in Khartoum, Sudan by one-step real-time PCR Janine Michel, Robert Koch Institute, Berlin, Germany

42

6th European Congress of Virology

WS-19 Viral Gene Expres-sion – Transcription, Translation

21th Oct. 201617:15 – 19:00

Foyer D-G

P19-1 Comparing the activity of the non-coding control region of 13 human polyomaviruses regarding bi-directional expression of the early and late viral gene regionElvis Ajuh Tasih, University of Basel/Institut für Medizinische Mikrobiologie, Basel, Switzerland

P19-2 hnRNP L controls HPV16 mRNA splicing in an Akt-kinase-dependent mannerStefan Schwartz, Lund University, Lund, Sweden

P19-3 The human cytomegalovirus (HCMV) immediate-early protein IE2p86 negatively regulates transcription of lentiviral vectors leading to a shut-down of transgene expressionNina Reuter, Institute of Clinical and Molecular Virol-ogy, Erlangen, Germany

P19-4 HHV-6 U94 inhibits motility, migration and inva-siveness of human breast cancer cells by modula-tion of src signaling pathwayFrancesca Caccuri, University of Brescia, Brescia, Italy

P19-5 HDV-GT3 demonstrates increased intrahepatic activity, distinct characteristics of the HDAg and enhanced HBV suppression compared to HDV-GT1 in infected humanized miceKatja Giersch, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

P19-6 Decoding the Argonaute/viral RNA interaction map during HIV-1 replication using Ago2 HITS-CLIPSarah Gallois-Montbrun, Institut Cochin – Inserm, U1016 – CNRS, UMR8104 – Paris Descartes University, Paris, France

P19-7 Expression of hemagglutinin gene of avian infl u-enza virus subtype H9 in Leishmania tarentolaeJahan Ara Begum, Institute of Virology, Leipzig, Germany

P19-8 Coronavirus Nsp14 modulates the innate immune responseSonia Zuñiga, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain

P19-9 Structure dependent procession of non-structural polyprotein 7-10 and formation of a replication-transcription complex of SARS CoronavirusBoris Krichel, Heinrich Pette Institute, Hamburg, Germany

P19-10 N-terminal domain of Open Reading Frame 3 (ORF3) gene of Porcine Epidemic Diarrhea Virus in-ducing cell death by cell arresting at the G1 phaseJihoon Ryu, Chungnam National University, Daejeon, Korea, Republic of

P19-12 The role of translation termination factors in foot-and-mouth disease virus 2A peptide driven translational recodingMan Balola, Newcastle University, Newcastle, United Kingdom

P19-13 Investigation into the structure of the nascent viral ´2A´ peptide in the ribosomal exit tunnel.Pippa Harvey, Newcastle University, Newcastle upon Tyne, United Kingdom

P19-14 Comparision of expression effectiveness of infec-tious pancreatic necrosis virus (IPNV) VP2 protein in three different Escherichia coliHarun Albayrak, Ondokuz Mayis University, Samsun, Turkey

WS-20 Viral Vectors for Vaccine Design

21th Oct. 201617:15 – 19:00

Hall E

P20-1 The protective role of tissue resident T cells against infl uenza infection by a CMV-based vaccine vectorXiaoyan Zheng, Helmholtz Centre for Infection Research, Braunschweig, Germany

P20-4 DNA-launched RNA virus replicons based on yel-low fever virus 17DNadia Oreshkova, Leiden University Medical Center, Leiden, Netherlands

WS-21 Viral Evolution and Resistance

19th Oct. 201618:00 – 20:00

Foyer D-G

P21-1 PAMM: A versatile approach exploring evolution across large phylogenies using mutational mappingHui Chen, Genome Institute of Singapore, Singapore, Singapore

P21-2 Origin and dissemination of hepatitis B virus genotype C in East Asia revealed by phylodynamic analysis and historical correlatesHsin-Fu Liu, Mackay Memorial Hospital, New Taipei city, Taiwan, Republic of China

P21-3 Comparative study of in vivo evolution of hepacivi-ral glycoproteins in humans and horsesDaniel Todt, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany

P21-4 Production and characterisation of a hepatitis C virus cell culture (HCVcc) panel of patient-derived E1E2 glycoproteins for use in vaccine and therapy research Richard A Urbanowicz, The University of Nottingham, Nottingham, United Kingdom

P21-5 Role of the PB1 protein in the fi delity of the infl u-enza virus polymerase complexFlorian Andrieux, Institut Pasteur, Paris, France

P21-7 Intrahost norovirus evolution in chronic norovirus infectionAndrej Steyer, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

P21-8 Sequence variability of Puumala virus strain cg1820 Agnieszka M, Szemiel, MRC – University of Glasgow Centre for Virus Research, Glasgow, United Kingdom

P21-9 Intertypic recombination of human parechovirus 4 isolated from infants with sepsis-like diseaseTeemu Smura, University of Turku, Turku, Finland

WS-22 Epidemiology and Surveillance

19th Oct. 201618:00 – 20:00

Hall D

P22-1 Detection of Canine parvovirus type 2 by PCR in Konya IRMAK Dik, University of Selcuk /Faculty of Veterinary Medicine, Konya, Turkey

P22-2 Accurate diagnosis of human Bocavirus 1 Infection by RT-PCR, qPCR and serologyMAN XU, University of Helsinki, Helsinki, Finland

P22-3 Molecular detection and phylogenetic analysis of Avipoxvirus strains isolated from different bird species Omid Madadgar, University of Tehran, Tehran, Iran, Islamic Republic of

Poster Sessions

43

P22-5 CMV seroprevalence among women of childbear-ing age and burden of congenital cytomegalovirus infection in PolandTomasz Dzieciatkowski, Medical University of Warsaw, Warsaw, Poland

P22-6 Molecular detection and genotyping of enteric viruses in children with acute gastroenteritis in Casablanca, MoroccoJalal Nourlil, Institut Pasteur du Maroc, Casablanca, Morocco

P22-8 Application of molecular genotyping to determine prevalence of HPV strains among Kazakhstan women with abnormal Pap smear cytologyAzliyati Azizan, Nazarbayev University, Astana, Kazakhstan

P22-9 Detection of human papillomavirus in tissue biop-sies from patients with head and neck squamous cell carcinoma in the Free State province, South Africa using E6 multiplex hemi-nested type specifi c PCRTumelo Sekee, University of the Free State, Bloemfon-tein, South Africa

P22-12 Seroprevalence of Hepatitis B, C and associated risk factors in hemodialysis units in BaghdadBaydaa Alabdali, Almustansiria, Baghdad, Iraq

P22-15 Molecular epidemiology of Delta virus strains circulating in Central ItalyAnna Rosa Garbuglia, INMI L SPALLANZANI IRCCS, Rome, Italy

P22-16 Molecular characterisation of British Equine Infec-tious Anaemia cases, 1975-2012Bhudipa Choudhury, APHA, Weybridge, United Kingdom

P22-17 Molecular epidemiological and serological studies of bovine leukemia virus (BLV) infection in ThailandYeun-Kyung Shin, Animal and Plant Quarantine Agency, Gimcheon, Korea, Republic of

P22-20 Molecular analyses of canine infl uenza viruses H3N2 isolated in Korea during 2013-2014Yeun-Kyung Shin, Animal and Plant Quarantine Agency, Gimcheon-si, Korea, Republic of

P22-23 Survey of causative agents for acute respiratory infections among patients in Khartoum- State, Sudan, 2010-2011Khalid Enan, Central Laboratory – The Ministry of Higher Education and Scientifi c Research, Khartoum, Sudan

P22-24 A study of Newcastle disease virus obtained from exotic caged birds in Tehran between 2009 and 2010 Omid Madadgar, University of Tehran, Tehran, Iran, Islamic Republic of

P22-25 Genomic characterization of novel avian paramyxo-virus isolated from wild birds in KoreaKang-Seuk Choi, Animal and Plant Quarantine Agency, Gimcheon, Korea, Republic of

P22-26 Epidemiologic investigations of a hospital cluster of Middle East Respiratory Syndrome outbreak in South Korea, 2015Changhwan Lee, KCDC, Cheongju, Korea, Republic of

P22-27 Hospital outbreaks of Middle East Respiratory Syndrome in Daejeon, South KoreaJung Wan Park, KCDC, Cheongju, Korea, Republic of

P22-28 Middle East Respiratory Syndrome Coronavirus outbreak in the Republic of Korea, 2015Seung Woo Kim, KCDC, Cheongju, Korea, Republic of

P22-29 Risk factors for transmission of Middle East res-piratory syndrome coronavirus infection during the 2015 outbreak in South KoreaChanghwan Lee, KCDC, Cheongju, Korea, Republic of

P22-30 Epidemiologic features of the fi rst MERS outbreak in Korea: focus on Pyeongtaek St. Mary’s HospitalKyung Min, Kim KCDC, Cheongju, Korea, Republic of

P22-31 The identifi cation and characterization of pestivirus infections circulating among small ruminants, Turkey Tuba Cigdem Oguzoglu, Ankara University Veterinary Faculty, Ankara, Turkey

P22-33 Continuous emergence and disappearance of sub-lineages of norovirus GII.4 Sydney 2012 during 2012-2016 in Hong KongKirsty Kwok, The Chinese University of Hong Kong, Hong Kong, Hong Kong

P22-34 Investigation of Bovine Enteric Caliciviruses among diarrheic calves in TurkeyIlke Karayel, Ankara University Faculty of Veterinary Medicine, Ankara, Turkey

P22-35 Chikungunya and West Nile Viruses in Rwanda: Seroprevalence among blood donors and spread of mosquito-vectorsEric Seruyange, University of Gothenburg, Götenburg, Sweden

P22-38 Preparation of recombinant antigen for serological detection of African hantavirusesDeborah Damane, University of the Free State, Bloemfontein, South Africa

P22-39 The molecular characterisation of akabane virus from severe outbreak in 2015, TurkeyFERAY Alkan, Ankara University Faculty of Veterinary Medicine, Ankara, Turkey

P22-40 A systematic review of genetic diversity of human rotavirus circulating in South KoreaVan Thai Than, Chung-Ang University, Seoul, Korea, Republic of

P22-41 Genotyping and determining the distribution of prevalent G and P types of group A bovine rotavi-ruses between 2010 and 2012 in IranOmid Madadgar, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran, Islamic Republic of

P22-42 Genetic diversity and evolutionary analysis of rotavirus G2P[4] strains in South Korea: insights into the human and animal reassortment after vaccine introduction Thanh Hien Dang, Chung-Ang University, Seoul, Korea, Republic of

WS-23 Infection of the Im-munocompromised

19th Oct. 201618:00 – 20:00

Hall E

P23-1 The potential role of viral infections on appearance of graft-versus-host disease on adult recipients of allogeneic haematopoietic stem cell transplanta-tion in early post-transplant periodTomasz Dzieciatkowski, Medical University of Warsaw, Warsaw, Poland

P23-2 Immunosuppressive therapy affects EBV- and HCMV-specifi c T-cell responses in patients with Systemic Lupus ErythematosusIrene Cassaniti, IRCCS Policlinico San Matteo, Pavia, Italy

44

6th European Congress of Virology

P23-3 Comparison of real-time PCR to ELISA for the detection of human Cytomegalovirus infection in renal transplant patients in the SudanKhalid Enan, Central Laboratory – The Ministry of Higher Education and Scientifi c Research, Khartoum, Sudan

P23-5 Human Immunodefi ciency Virus and Strongyloi-des stercoralis infection in the United States of America, Laia JimenaVazquez-Guillamet Yale New Haven Health-Bridge-port Hospital, Bridgeport, United States

WS-24 Zoonotic Viruses21th Oct. 201617:15 – 19:00

Hall D

P24-1 Hepatitis E Virus prevalence in British pigs at the time of slaughterBhudipa Choudhury, APHA, Weybridge, United Kingdom

P24-2 Molecular tracing of Hepatitis E virus in domestic pigs and wild boars from Corsica and possible foodborne transmissions in continental FranceNicole Pavio, ANSES, Maisons-Alfort, France

P24-3 Close genetic relatedness between human and swine hepatitis E viruses in Hong KongKirsty Kwok, The Chinese University of Hong Kong, Hong Kong, Hong Kong

P24-4 Infl uenza A virus particles outside their hosts: is the Hemagglutinin a key factor for virus durability?Thomas Labadie, Institut Pasteur, Paris, France

P24-5 Synthetically derived bat infl uenza A-like viruses reveal a cell type- but not species-specifi c tropismMartin Schwemmle, Institute of Virology, University Medical Center Freiburg, Freiburg, Germany

P24-6 Role of the ciliary activity of the airway epithelium in the virus-host interaction Yuguang Fu, University of Veterinary Medicine Han-nover, Hannover, Germany

P24-7 Important viruses with zoonotic potential in South African bats: infl uenza A and hantavirusesKarmistha Poovan, Stellenbosch University, Cape Town, South Africa

P24-8 Development of minireplicon systems for Tula and Dobrava-Belgrade hantavirusesKirill Nemirov, Institute Pasteur, Paris, France

P24-9 Human primary brain cells, a relevant model to study Tick-Borne Encephalitis Virus-induced neuropathogenesisMazigh Fares, UMR 1161 Virology INRA/ANSES/ENVA, Maisons-Alfort, France

P24-10 In vitro model of vector to host transmission: Langat and tick-borne encephalitis virus (LGTV and TBEV) infection of an embryonic Ixodes ricinus tick cell line and rat organotypic cerebellar culture slices to investigate viral quasispecies dynamicsNicole Lenz, University of Bern, Bern, Switzerland

P24-11 Zoonotic variegated squirrel bornavirus 1: Detec-tion in additional squirrel of two speciesKore Schlottau, Friedrich-Loeffl er-Institut, Greifswald - Insel Riems, Germany

P24-12 Development of serological assays for the detec-tion of henipavirus specifi c antibodiesKerstin Fischer, Friedrich-Loeffl er-Institut, Greifswald - Insel Riems, Germany

P24-13 Molecular epidemiology of an outbreak of Lymphocytic Choriomeningitis mammarenavirus infection in rodents and primates at a zoo in the United Kingdom Okechukwu, Onianwa, University of Nottingham, Not-tingham, United Kingdom

P24-14 Development and evaluation of a competitive enzyme-linked immunosorbent assay using a monoclonal antibody for diagnosis of severe fever with thrombocytopenia syndrome virus (SFTSV) in bovine seraYeun-Kyung Shin, Animal and Plant Quarantine Agency, Gimcheon, Korea, Republic of

WS-25 Curative Strategies for Virus Eradication

20th Oct. 201617:30 – 19:30

Hall E

P25-1 Modifi ed sabin 2 polioviruses for use as an oral-live attenuated vaccine post-eradicationMatthijn de Boer, Intravacc, Bilthoven, Netherlands

WS-26 Virus Discovery, Typing and Metage-nomics

21th Oct. 201617:15 – 19:00

Hall D

P26-1 Employment of next generation sequencing tech-niques for pathogen discovery in cerebrospinal fl uid of patients with encephalitis and meningitisCristina Freitas Nunes, Institute of Tropical Medicine of São Paulo, São Paulo, Brazil

P26-2 Diagnostic metagenomics from respiratory samples signifi cantly enhances the detection rate of pathogens in allogenic HSCT patients with pulmonary complications Nicole, Fischer, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

P26-3 Circulation of infl uenza D virus in cattle in ItalyChiara Chiapponi, Istituto Zooprofi lattico Sperimen-tale della Lombardia e dell’Emilia Romagna, Parma, Italy

P26-5 Discovery of novel avian polyomavirusesKristin Heenemann, Leipzig University, Faculty of Veterinary Medicine, Leipzig, Germany

P26-6 PCR standardization for full Trichodysplasia Spinulosa-associated Polyomavirus (TSPyV) to sequencing using sanger methodology and next-generation sequencing Paulo Roberto Urbano, Institute of Tropical Medicine of São Paulo, São Paulo, Brazil

P26-7 Retrospective genetic and phylogenetic study of orthobunyaviruses circulating in RussiaAlexey Mikhailovich Shchetinin, Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russian Federation

P26-8 The molecular-biological properties and physico-chemical characterization of an iridovirus from mosquito Aedes fl avescentsYuriy Rud, Institute of Fisheries, Kyiv, Ukraine

P26-9 Unusual large dsDNA viruses discovered among genome data of 15 different fi shAmr Aswad, University of Oxford, Oxford, United Kingdom

Poster Sessions

45

WS-27 Vector Borne Infec-tions

21th Oct. 201617:15 – 19:00

Hall D

P27-1 Evidence of wild birds participating in Toscana virus dissemination and perpetuationSabri Hacioglu, Ankara University Faculty of Veterinary Medicine, Ankara, Turkey

P27-2 Latest Zika virus outbreak: lessons learnt from the perspective of the “European Virus Archive goes Global (EVAg)” EU funded consortiumChristine Prat, Aix-Marseille Univ – Institut de Re-cherche pour le Développement – Ecole des Hautes Etudes en Santé Publique, Marseille, France

P27-3 First imported case of Zika virus infection in China, diagnosis and genomic analysisShuo Zhang, National Institute for Viral Disease Con-trol and Prevention, China CDC, Beijing, China

P27-4 Virus and antibody kinetics in acute Zika virus infection Luisa Barzon, University of Padova, Padova, Italy

P27-5 Persistent shedding of Zika virus RNA in semenLuisa Barzon, University of Padova, Padova, Italy

P27-6 Development and evaluation of an enzyme-linked immunosorbent assay for the detection of IgM an-tibodies to Zika Virus in human serum and plasmaElke Heck, NovaTec Immundiagnostica GmbH, Dietzenbach, Germany

P27-7 Arbo-MIA: An innovative platform for accurate high-throughput diagnosis and surveillance of Zika virus and arboviral infectionsJessica Vanhomwegen, Institut Pasteur, Paris, France

P27-10 Concurrent micro-RNA mediated silencing of tick-borne fl avivirus replication in tick vector and in the brain of vertebrate hostKonstantin A. Tsetsarkin, NIAID, Bethesda, United States

P27-11 Mosquito borne infectious diseases across borders, risks, challenges and mangement with reference to dengue virusMamdouh El Bahnasawy, Military Medical Academy, Cairo, Egypt

P27-12 Proteomic profi ling of Aedes albopictus infected with chikungunya virus or dengue virus provides new insights into vector-arbovirus interactionsVincent Legros, Pasteur Institut, Paris, France

P27-13 Dengue fever presenting as acute airway obstruc-tion: a case reportManidipa Majumdar, R G Kar Medical College and Hospital, Kolkata, India

P27-14 MK3, a novel host factor, is essential for Chikungu-nya virus protein translation in vitroPrabhudutta Mamidi, Institute of Life Sciences, Bhubaneswar, India

P27-15 Characterization of nsP1 and nsP2 interaction of Chikungunya virusSameer Kumar, Institute of Life Sciences, Bhubane-swar, India

P27-16 Chikungunya importation risks from Thailand to Europe regions during the period of 2008 – 2015: What they meanHatsadee Appassakij, Prince of Songkla University, Faculty of Medicine, Hat Yai, Thailand

P27-17 A temporary imported chikungunya virus infec-tion in non-immune travellers returning from the outbreak activity at popular tourist destinations in Southern Thailand during 2008 – 2015Hatsadee Appassakij, Prince of Songkla University, Faculty of Medicine, Hat Yai, Thailand

P27-18 Diagnosis of West Nile virus infection: Experience in a reference laboratory, Italy, 2008 – 2015Luisa Barzon, University of Padova, Padova, Italy

P27-19 Identifi cation of T cell epitopes on the nucleopro-tein of Crimean-Congo haemorrhagic fever virusDominique Goedhals, National Health Laboratory Service/University of the Free State, Bloemfontein, South Africa

P27-20 A case of Crimean-Congo hemorrhagic fever and a general review in EgyptMamdouh El Bahnasawy, Military Medical Academy, Cairo, Egypt

P27-21 Crimean-Congo haemorrhagic fever virus detected in patient with suspected rickettsia infection: increasing awareness within endemic countries and for travelers Felicity Burt, NHLS and University of the Free State, Bloemfontein, South Africa

P27-22 Molecular detection of Crimean-Congo hemor-rhagic fever virus (CCHFV) in tick samples but not in blood and milk samples in northern TurkeyHarun Albayrak, Ondokuz Mayis University, Samsun, Turkey

P27-23 Rift Valley fever virus P78 glycoprotein as a mos-quito specifi c virulence factorFelix Kreher, University of Glasgow, Glasgow, United Kingdom

P27-24 Epidemiological investigation of severe fever with thrombocytopenia syndromeShuo Zhang, National Institute for Viral Disease Con-trol and Prevention, China CDC, Beijing, China

46

6th European Congress of Virology

47

Speakers‘ Index Page

Akkutay-Yoldar, Zeynep Ankara University, Faculty of Veterinary Medicine, Ankara, Turkey. . . . . . . . . 23

Allen, Todd Ragon Institute of MGH, MIT and Harvard, Cambridge MA, USA . . . . . 30, 31

Andrei, Graciela Rega Institute, KU Leuven, Belgium . . . . . . . . . . . . . . . . . 20

Ar Gouilh, Meriadeg Institut Pasteur, Paris, France . . . . . . . . . . . . . . . . . . . . 31

Asbach, Benedikt University of Regensburg, Regensburg, Germany . . . . . . . . . . . . 29

Bahar, Mohammad Waleed Division of Structural Biology, Oxford, UK . . . . . . . . . . . . . . . 29

Bailly, Benjamin Institute for Glycomics, Gold Coast, Australia . . . . . . . . . . . . . . 25

Bartenschlager, Ralf University Hospital Heidelberg, Germany . . . . . . . . . . . . . . . 28

Bartusch, Christina University Medical Center of the

Johannes Gutenberg University Mainz, Mainz, Germany . . . . . . . . . 22

Barzon, Luisa University of Padova, Padova, Italy. . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Baumert, Thomas F. INSERM, University of Strasbourg, France. . . . . . . . . . . . . . . . . . . . . 31, 55

Baz-Martínez, Maite Centro de Investigación en Medicina Molecular y Enfermedades Crónicas

(CiMUS), Santiago de Compostela, Spain . . . . . . . . . . . . . . . . . . . . . . . 28

Beer, Martin Friedrich-Loeffl er-Institut, Greifswald-Insel Riems, Germany . . . . . . . . . . . . 27

Belarbi, Essia CEA, Fontenay aux Roses, France . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

Benkirane, Monsef Institut de Génétique Humaine, Montpellier, France . . . . . . . . . . . . . . . . 55

Benn, Paul ViiV Healthcare, London, UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Berezin, Vladimir Institute of Microbiology and Virology, Almaty, Kazakhstan . . . . . . . . . . . . 26

Berlioz-Torrent, Clarisse INSERM, Paris, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Billerbeck, Eva The Rockefeller University, New York, USA . . . . . . . . . . . . . . . . . . . . . . 22

Biquand, Elise Institut Pasteur, Paris, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Blanc, Stéphane INRA-CIRAD-Supagro, Montpellier, France . . . . . . . . . . . . . . . . . . . . . . 32

Blöcker, Johanna University Medical Center Hamburg-Eppendorf, Hamburg, Germany . . . . . . 22

Boianelli, Alessandro Helmholtz Centre for Infection Research, Braunschweig, Germany . . . . . . . . 24

Bosse, Jens Bernhard Heinrich Pette Institute, Leibniz Institute for Experimental Virology,

Hamburg, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Bresk, C. Anika Medical University Innsbruck, Innsbruck, Austria . . . . . . . . . . . . . . . . . . . 29

Brown, Martha University of Toronto, Toronto, Canada . . . . . . . . . . . . . . . . . . . . . . . . 28

Brown, Richard J. P. TWINCORE, Centre for Experimental and Clinical Infection Research,

Hannover, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Buchholz, Frank TU Dresden, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31

Buggisch, Peter IFI Medicine, Hamburg, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . 55

Burkard, Christine University of Edinburgh, Roslin, UK . . . . . . . . . . . . . . . . . . . . . . . . . . 26

Caignard, Grégory UMR 1161 ANSES-INRA-ENVA, Maisons-Alfort, France. . . . . . . . . . . . . . . 26

Campadelli-Fiume, Gabriela University of Bologna, Italy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21, 28

Carroll, Miles W. Public Health England, Salisbury, UK. . . . . . . . . . . . . . . . . . . . . . . . . . 23

Castaño-Rodríguez, Carlos Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain . . . . . . . . . . 28

Catanese, Maria Teresa King’s College London, London, UK . . . . . . . . . . . . . . . . . . . . . . . . . . 22

Chappell, Joe University of Nottingham, Nottingham, UK . . . . . . . . . . . . . . . . . . . . . . 32

Ching, Wilhelm Heinrich Pette Institute, Leibniz Institute for Experimental Virology,

Hamburg, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27

Chiocca, Susanna European Institute of Oncology, Milano, Italy . . . . . . . . . . . . . . . . . . . . 26

Colpitts, Che C. Inserm U1110, Institut de Recherche sur les Maladies Virales et Hépatiques,

Strasbourg, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Cornberg, Markus Medical University Hannover, Hannover, Germany. . . . . . . . . . . . . . . . . . 55

6th European Congress of Virology

48

Speakers‘ Index Page

Cortez-San Martín, Marcelo Universidad de Santiago de Chile, Santiago, Chile . . . . . . . . . . . . . . . . . 29

Cullen, Bryan R. Duke University Medical Center, Durham NC, USA . . . . . . . . . . . . . . . . . 28

Czech-Sioli, Manja University Medical Center Eppendorf, Hamburg, Germany . . . . . . . . . . . . 31

Dahlke, Christine University Medical Center Eppendorf, Hamburg, Germany . . . . . . . . . . . . 26

Dai, Meiling Utrecht University, Utrecht, The Netherlands . . . . . . . . . . . . . . . . . . . . . 31

Dallmeier, Kai KU Leuven - University of Leuven, Leuven, Belgium . . . . . . . . . . . . . . . . . 26

Dao Thi, Viet Loan Rockefeller University, New York, USA . . . . . . . . . . . . . . . . . . . . . . . . . 31

Davidson, Irit Kimron Veterinary Institute, Bet Dagan, Israel . . . . . . . . . . . . . . . . . . . . 22

De Spiegelaere, Ward Ghent University, Belgium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22

de Haan, Cornelis A.M. Utrecht University, Utrecht, The Netherlands . . . . . . . . . . . . . . . . . . . . . 30

Declercq, Marion Institut Pasteur, Paris, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Dehn, Sandra Michaela University Clinic Tübingen, Tübingen, Germany . . . . . . . . . . . . . . . . . . . 20

Delwart, Eric University of California, San Francisco CA, USA . . . . . . . . . . . . . . . . . 31, 32

Deschermeier, Christina Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany . . . . . . . 22

Desole, Giovanna University of Padova, Padova, Italy. . . . . . . . . . . . . . . . . . . . . . . . . . . 23

Diederich, Sandra Friedrich-Loeffl er-Institut, Greifswald - Insel Riems, Germany . . . . . . . . . . . 22

Diskin, Ron Weizmann Institute of Science, Rehovot, Israel . . . . . . . . . . . . . . . . . . . . 21

Drosten, Christian University of Bonn, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Dubich, Tatyana Helmholtz Centre for Infection Research, Braunschweig, Germany . . . . . . . . 27

Dudek, Alexandra University of Freiburg, Freiburg, Germany . . . . . . . . . . . . . . . . . . . . . . 20

Durantel, David INSERM, Lyon, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Fargette, Denis IRD, Université Montpellier 2, Montpellier, France. . . . . . . . . . . . . . . . . . 27

Fehse, Boris Univesity Medical Center Eppendorf, Hamburg, Germany . . . . . . . . . . . . . 55

Feldmann, Heinz NIAID, NIH, Hamilton MT, USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Fertey, Jasmin Fraunhofer-Institute for Cell Therapy and Immunology, Leipzig, Germany . . . . 26

Fiorentini, Simona University of Brescia, Brescia, Italy . . . . . . . . . . . . . . . . . . . . . . . . . 25, 30

Furnon, Wilhelm UMR 754 INRA - University Claude Bernard Lyon 1, IVPC, Lyon, France . . . . . 32

Ganem, Don Novartis Institutes for Biomedical Research, Emeryville CA, USA . . . . . . . . . 20

Ganges, Llilianne IRTA, Barcelona, Spain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27

Garcia, J. Victor University of North Carolina, Chapel Hill NC, USA. . . . . . . . . . . . . . . . . . 23

Garzino Demo, Alfredo University of Padova, Padova, Italy. . . . . . . . . . . . . . . . . . . . . . . . . . . 23

Geijtenbeek, Teunis B. University of Amsterdam, The Netherlands . . . . . . . . . . . . . . . . . . . . . . 20

Gonzalez-Almela, Esther Universidad Autónoma de Madrid, Madrid, Spain . . . . . . . . . . . . . . . . . . 20

Goulder, Philip University of Oxford, UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22

Grandi, Nicole University of Cagliari, Monserrato (Cagliari), Italy . . . . . . . . . . . . . . . . . . 32

Greber, Urs University of Zurich, Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Hage, Elias Hannover Medical School, Hannover, Germany . . . . . . . . . . . . . . . . . . . 30

Harrer, Thomas Universitätsklinikum Erlangen, Erlangen, Germany . . . . . . . . . . . . . . . 22, 31

Hassan, Ebrahim University of Freiburg, Freiburg, Germany . . . . . . . . . . . . . . . . . . . . . . 20

Hedman, Klaus University of Helsinki, Helsinki, Finland . . . . . . . . . . . . . . . . . . . . . . . . 30

Hirsch, Hans University of Basel, Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Hoffmann, Hans-Heinrich The Rockefeller University, New York, USA . . . . . . . . . . . . . . . . . . . . . . 22

Horemheb-Rubio, Gibran National Institute of Medical Science and Nutrition, Mexico City, Mexico . . . . 31

Imperiale, Michael J. University of Michigan, Ann Arbor MI, USA . . . . . . . . . . . . . . . . . . . . . . 21

Izquierdo, Laure AP-HP Paul Brousse Hospital, Villejuif, France . . . . . . . . . . . . . . . . . . . . 23

Jo, Wendy K. University of Veterinary Medicine, Hannover, Germany . . . . . . . . . . . . . . . 32

Kaiser, Rolf University of Cologne, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

49

Kellam, Paul Welcome Trust Sanger Institute, Cambridge, UK . . . . . . . . . . . . . . . . . . 31

Khou, Cecile Institut Pasteur, Paris, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

Klingen, Thorsten Ralf Helmholtz Centre for Infection Research, Braunschweig, Germany . . . . . . . . 30

Koethe, Susanne Friedrich-Loeffl er-Institut, Greifswald-Insel Riems, Germany . . . . . . . . . . . . 22

Komatsu, Tetsuro Université de Bordeaux, Bordeaux, France . . . . . . . . . . . . . . . . . . . . . . 20

Koopmans, Marion Erasmus MC, Rotterdam, The Netherlands . . . . . . . . . . . . . . . . . . . . 30, 31

Kotta-Loizou, Ioly Imperial College London, London, UK . . . . . . . . . . . . . . . . . . . . . . . . 32

Lavillette, Dimitri Institut Pasteur Shanghai, Shanghai, China . . . . . . . . . . . . . . . . . . . . 21, 32

Lazear, Helen M. University of North Carolina, Chapel Hill NC, USA. . . . . . . . . . . . . . . . . . 32

Leopardi, Stefania Istituto Zooprofi lattico Sperimentale delle Venezie, Legnaro, Italy . . . . . . . . 31

Li, Sai University of Oxford, Oxford, UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Liljeström, Peter Karolinska Institutet, Stockholm, Sweden . . . . . . . . . . . . . . . . . . . . . . . 29

Lilleri, Daniele Fondazione IRCCS Policlinico San Matteo, Pavia, Italy . . . . . . . . . . . . . . . 22

Limonta, Daniel University of Alberta, Edmonton, Canada . . . . . . . . . . . . . . . . . . . . . . . 23

Lingappa, Vishwanath R. Prosetta Biosciences, San Francisco CA, USA . . . . . . . . . . . . . . . . . . . . 22

Lotke, Rishikesh Hanover Medical School, Hannover, Germany . . . . . . . . . . . . . . . . . . . . 27

Lucifora, Julie University of Lyon, Lyon, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55

Lusic, Marina University of Heidelberg, Heidelberg, Germany . . . . . . . . . . . . . . . . . . . 55

Malim, Michael H. King’s College London, UK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Masucci, Maria Karolinska Institutet, Stockholm, Sweden . . . . . . . . . . . . . . . . . . . . . . . 23

Mcilroy, Dorian INSERM, Center for Research in Transplantation and Immunology (CRTI),

Nantes, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Mesalam, Ahmed Atef Ghent University, Ghent, Belgium . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Mettenleiter, Thomas Friedrich-Loeffl er-Institut, Greifswald-Insel Riems, Germany . . . . . . . . . . 22, 26

Moreno del Olmo, Elena Centro de Biología Molecular Severo Ochoa-CSIC-UAM, Madrid, Spain . . . . . 30

Münz, Christian University of Zurich, Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

Muscolino, Elena Heinrich Pette Institute, Leibniz Institute for Experimental Virology,

Hamburg, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Nikonova, Aleksandra Mechnikov Research Institute for Vaccines and Sera,

Moscow, Russian Federation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25

Nour, Islam King Saud University, Riyadh, Saudi Arabia . . . . . . . . . . . . . . . . . . . . . . 30

Oestereich, Lisa Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany . . . . . . . 28

Osterhaus, Albert University of Veterinary Medicine Hannover, Germany . . . . . . . . . . . . . 31, 32

Pantaleo, Guiseppe University of Lausanne, Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . 26

Papa, Anna Aristotle University of Thessaloniki, Greece . . . . . . . . . . . . . . . . . . . . . . 28

Peralta, Zuleyma Icahn School of Medicine at Mount Sinai, New York, USA . . . . . . . . . . . . . 28

Pesavento, Patricia School of Veterinary Medicine, UC Davis, Davis, USA . . . . . . . . . . . . . . 23, 26

Pfänder, Stephanie TWINCORE - Centre for Experimental and Clinical Infection Research,

Hannover, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Pietsch, Corinna Leipzig University, Leipzig, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . 25

Ping, Yueh-Hsin National Yang-Ming University, Taipei, Taiwan, Republic of China . . . . . . . . . 21

Pischke, Sven University Medical Center Eppendorf, Hamburg, Germany . . . . . . . . . . . . 25

Ploss, Alexander Princeton University, Princeton NJ, USA. . . . . . . . . . . . . . . . . . . . . . . . 23

Quirin, Tania University of Helsinki, Helsinki, Finland . . . . . . . . . . . . . . . . . . . . . . . . 21

Raj, V. Stalin Department of Viroscience, Erasmus Medical Center,

Rotterdam, The Netherlands . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

Rey, Félix A. Institut Pasteur, Paris, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Riedel, Christiane Vetmeduni Vienna, Vienna, Austria. . . . . . . . . . . . . . . . . . . . . . . . . . . 21

6th European Congress of Virology

50

Speakers‘ Index Page

Rivas, Carmen CIMUS, Santiago de Compostela, Spain . . . . . . . . . . . . . . . . . . . . . . . 27

Rockstroh, Jürgen Bonn University Hospital, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Rodriguez, Estefania Heinrich Pette Institute, Leibniz Institute for Experimental Virology,

Hamburg, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27

Rübsamen-Schaeff, Helga University of Frankfurt, Wuppertal, Germany . . . . . . . . . . . . . . . . . . . . . 32

Ruibal, Paula Heinrich Pette Institute, Leibniz Institute for Experimental Virology,

Hamburg, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Samreen, Baila Heinrich Heine University of Düsseldorf, Düsseldorf, Germany . . . . . . . . . . 26

Sas, Miriam A. Friedrich-Loeffl er-Institut, Greifswald-Insel Riems, Germany . . . . . . . . . . . . 30

Scheel, Troels K. H. University of Copenhagen, Copenhagen, Denmark . . . . . . . . . . . . . . . . . 28

Schlabe, Stefan University Hospital Bonn, Bonn, Germany. . . . . . . . . . . . . . . . . . . . . . . 24

Schmid, Michael A. University of California Berkeley, Berkeley, USA . . . . . . . . . . . . . . . . . . . 32

Schmiedel, Dominik Hebrew University of Jerusalem, Jerusalem, Israel. . . . . . . . . . . . . . . . . . 20

Schoofs, Till The Rockefeller University, New York City, USA. . . . . . . . . . . . . . . . . . . . 28

Schubert, Grit Robert Koch-Institute, Berlin, Germany . . . . . . . . . . . . . . . . . . . . . . . . 31

Seuberlich, Torsten University of Bern, NeuroCenter-Division of Neurological Sciences,

Bern, Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

Shah, Pranav Uniklinikum, Heidelberg Universität, Heidelberg, Germany . . . . . . . . . . . . 24

Shaw Stewart, Patrick Douglas Instruments Ltd, Hungerford, UK. . . . . . . . . . . . . . . . . . . . . . . 30

Shtykova, Eleonora Shubnikov Institute of Crystallography, Russian Academy of Sciences,

Moscow, Russian Federation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Sikorski, Mathieu UMR 1064 - CRTI, Nantes, France . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Snijder, Eric Leiden University Medical Center, Leiden, The Netherlands . . . . . . . . . . . . 28

Sola, Isabel CNB-CSIC, Madrid, Spain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Souza, William Marciel University of Sao Paulo, Ribeirão Preto, Brazil . . . . . . . . . . . . . . . . . . . . 32

Stech, Jürgen Friedrich-Loeffl er-Intitut, Greifswald - Insel Riems, Germany . . . . . . . . . . . . 28

Steinbach, Falko APHA, Addlestone, United Kingdom . . . . . . . . . . . . . . . . . . . . . . . . . 26

Steinhagen, Katja Institute for Experimental Immunology, Euroimmun AG, Luebeck, Germany . . 23

Stellbrink, Hans-Jürgen ICH, Hamburg, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25, 55

Stertz, Silke University of Zurich, Zurich, Switzerland . . . . . . . . . . . . . . . . . . . . . . . . 21

Stiasny, Karin Medical University of Vienna, Vienna, Austria . . . . . . . . . . . . . . . . . . . . 24

Strati, Katerina University of Cyprus, Nicosia, Cyprus . . . . . . . . . . . . . . . . . . . . . . . . . 27

Suarez, Nicolas MRC - University of Glasgow, Glasgow, UK . . . . . . . . . . . . . . . . . . . . . . 30

Szalmas, Anita University of Debrecen, Debrecen, Hungary . . . . . . . . . . . . . . . . . . . . . 27

Taher, Husam Institute for Infection Medicine, Kiel, Germany . . . . . . . . . . . . . . . . . . . . 29

Tai, Julie Weizmann Institute of Science, Rehovot, Israel . . . . . . . . . . . . . . . . . . . . 28

Teo, Su Hui Catherine Imperial College, London, United Kingdom . . . . . . . . . . . . . . . . . . . . . 28

Theiss, Juliane University Medical Center Eppendorf, Hamburg, Germany . . . . . . . . . . . . 27

Todt, Daniel TWINCORE - Centre for Experimental and Clinical Infection Research,

Hannover, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Tommasino, Massimo International Agency for Research on Cancer, Lyon, France . . . . . . . . . . . . 26

Tong, Jie University of Veterinary Medicine Hannover, Hannover, Germany . . . . . . . . . 31

Toppinen, Mari University of Helsinki, Helsinki, Finland . . . . . . . . . . . . . . . . . . . . . . . . 27

Tordo, Noël Institut Pasteur, Paris, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31

Towner, Jonathan CDC, Atlanta GA, USA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27

Trkola, Alexandra University of Zurich, Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Überla, Klaus Universitätsklinikum Erlangen, Erlangen, Germany . . . . . . . . . . . . . . . 20, 24

51

Uetrecht, Charlotte Heinrich Pette Institute, Leibniz Institute for Experimental Virology /

European XFEL, Hamburg, Germany. . . . . . . . . . . . . . . . . . . . . . . . . . 24

Ulbrich, Pavel University of Chemistry and Technology Prague, Prague, Czech Republic . . . . 24

Urban, Stephan University Hospital Heidelberg, Germany . . . . . . . . . . . . . . . . . . . . . . . 20

Urbanowicz, Richard A The University of Nottingham, Nottingham, UK . . . . . . . . . . . . . . . . . . . 30

Väisänen, Elina University of Helsinki, Helsinki, Finland . . . . . . . . . . . . . . . . . . . . . . . . 32

van Boemmel, Florian University Medical Center, Leipzig, Germany. . . . . . . . . . . . . . . . . . . . . 55

van der Poel, Wim H. Wageningen University, The Netherlands . . . . . . . . . . . . . . . . . . . . . . . 26

van der Werf, Sylvie University Paris Diderot-Sorbonne Paris Cité, Institut Pasteur,

Paris, France . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22

van Kuppeveld, Frank Utrecht University, Utrecht, The Netherlands . . . . . . . . . . . . . . . . . . . . . 21

Varjak, Margus MRC-University of Glasgow Centre for Virus Research, Glasgow, UK . . . . . . . 32

Vermeire, Tessa WIV-ISP, Ukkel, Belgium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Victorio, Carla Bianca Luena Temasek Life Sciences Laboratory, Singapore, Singapore. . . . . . . . . . . . . . 25

Viejo-Borbolla, Abel Hannover Medical School, Hannover, Germany . . . . . . . . . . . . . . . . . . . 27

Vietzen, Hannes Medical University of Vienna, Vienna, Austria . . . . . . . . . . . . . . . . . . . . 24

Volz, Asisa LMU Munich, Munich, Germany . . . . . . . . . . . . . . . . . . . . . . . . . . 26, 29

Vonderstein, Kirstin Umeå University, Umeå, Sweden . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Wagner, Ralf University of Regensburg, Regensburg, Germany . . . . . . . . . . . . . . . . 22, 26

Westhölter, Dirk University Hospital Hamburg-Eppendorf, Hamburg, Germany. . . . . . . . . . . 31

Wichgers Schreur, Paul Central Veterinary Institute, Part of Wageningen UR and Research Centre,

Lelystad, The Netherlands . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Widjaja, Ivy Utrecht University, Utrecht, The Netherlands . . . . . . . . . . . . . . . . . . . . . 21

Wolf, Dana Hadassah Medical Center, Jerusalem, Israel . . . . . . . . . . . . . . . . . . . . . 25

Wüstenhagen, Elena Johannes Gutenberg-University Mainz,

Mainz, Germany. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Yassine, Hadi Qatar University, Doha, Qatar. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Yim, Seung-Ae Inserm, U1110, Strasbourg, France . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Zakaryan, Hovakim Institute of Molecular Biology of NAS, Yerevan, Armenia . . . . . . . . . . . . . . 32

Zhernov, Yury National Research Center – Institute of Immunology FMBA of Russia,

Moscow, Russian Federation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32

52

6th European Congress of Virology

Congress Dinner & Networking Event

Join us for a communicative evening – think back to the lectures and discussions of the day and meet familiar and new branch colleagues! You can expect a buffet with local and interna-tional infl uence and corresponding drinks.

When? Friday, October 21, 19:00 - 24:00

Where? Congress Center Hamburg (Hall 3, Ground Floor)

Price: 55,00 f

Tickets for this evening were limited (“fi rst come – fi rst served”). Please ask at the registration desk if there are still tickets available.

Prices include 19% German VAT; in the name and for account of INTERPLAN AG, Kaiser-Wilhelm-Str. 93, 20355 Hamburg, Germany, Ust.-ID DE 21327487.

53

Symposia

Satellite Symposia

Frid

ay, 2

1th O

ctob

er

13

:15

– 1

4:4

5

HBV and HIV Cure

ANRS / DZIF Satellite SymposiumHBV and HIV Cure

Chairs Brigitte Autran, Brigitte Autran, Paris, France Martin Krönke, Cologne, Germany13:15 – 14:00 HBV

Functional genomics of HBV-host interactions to discover novel targets for viral cureThomas Baumert, Strassburg, France

Interactions between HBV, HDV and the hepatocytes: insights into the development of new antiviralsJulie Lucifora, Lyon, France

Stopping nucleos(t)die analogues in HBeAg negative chronic hepatitis B as concept to induce HBsAg declineMarkus Cornberg, Hannover, Germany

14:00 – 14:45 HIV

HIV integration and cellular fateMarina Lusic, Heidelberg, Germany

Understanding HIV latency in resting CD4 T cellsMonsef Benkirane, Montpellier, France

High-effi ciency TALEN-mediated knockout of HIV co-receptor CCR5 – a promising approach to confer resistance against R5-tropic HIVBoris Fehse, Hamburg, Germany

Satu

rday

, 22th

Oct

ober

13

:15

– 1

4:4

5

Emerging Zoonoses

Erasmus MC / Institut Pasteur Satellite SymposiumEmerging Zoonoses

Chairs

13:15 – 14:45

Programme to be announced on-site.

Challenges in Clinical Virology

ESV Satellite SymposiumChallenges in Clinical Virology

Chairs Knud Schewe, Hamburg, GermanyJulian Schulze zur Wiesch, Hamburg, Germany

Pushing the borders of HBV treatment: New treatment approaches and biomarkersFlorian van Boemmel, Leipzig, Germany

No more challenges in HCV?Peter Buggisch, Hamburg, Germany

Is it only the virus, stupid?Hans-Jürgen Stellbrink, Hamburg, Germany

Industry Symposia

Thur

sday

, 20th

Oct

ober

13

:15

– 1

4:1

5

Novel Technologies for

Improved Pathogen Detection

QIAGEN Satellite SymposiumNovel Technologies for Improved Pathogen Detection

Chairs

13:15 – 14:45

Instant success: setting new standards for safe and easy pathogen detec-tion by real-time PCRFrancesca Di Pasquale, Hilden, Germany

54

6th European Congress of Virology

55

Sponsors

We cordially thank the following companies for their support:

Platinum Sponsor:

Gold Sponsor:

Silver Sponsors:

We also thank MDPI for an unrestricted educational grant.

Support According to National Compliance Requirements

A listing of support according to national compliance requirements can be found atwww.eurovirology2016.eu/fsa-list.html.

The sponsoring companies do not have input into the development of the meeting.

56

6th European Congress of Virology

Exhibiton List

Acris-Antibodies-OriGene EU GERMANY G.03

Advanced Cell Diagnostics ITALY G.16

AID Diagnostika GmbH GERMANY G.18

altona Diagnostics GmbH GERMANY G.01

Biocartis NV BELGIUM G.17

BioLegend UNITED STATES OF AMERICA G.26

Biomatters NEW ZEALAND G.35

Bio-Rad Laboratories UNITED KINGDOM G.28

BIO-SYS GERMANY G.33

CTL Europe GmbH GERMANY G.29

dianova GmbH GERMANY G.24

DZIF Academy

Deutsches Zentrum für Infektionsforschung GERMANY G.38

eBioscience part of Themo Fischer Scientifi c AUSTRIA G.10

Eppendorf AG GERMANY G.13

EUROIMMUN AG GERMANY G.22

European Society for Virology GERMANY G.38

Gilead Sciences Europe Ltd. UNITED KINGDOM G.09

Heinrich Pette Institute,

Leibniz Institute for Experimental Virology GERMANY G.37

I&L Biosystems GERMANY G.23

Instand e.V. GERMANY G.34

Labotect Labor-Technik-Göttingen GmbH GERMANY G.19

LI-COR Biosciences GERMANY G.15

Lophius Biosciences GmbH GERMANY G.32

Luminex THE NETHERLANDS G.07

MACHEREY-NAGEL GmbH & CO. KG GERMANY G.30

MEDICAL WIRE AND EQUIPMENT UNITED KINGDOM G.02

Microbiology Society UNITED KINGDOM G.14

Mikrogen GmbH GERMANY G.04

Miltenyi Biotec GERMANY G.25

MSD SHARP & DOHME GMBH GERMANY G.11

Novatec Immundiagnostica GmbH GERMANY G.27

Oxford Immunotec UNITED KINGDOM G.36

PeproTech GERMANY G.12

PerkinElmer GERMANY G.21

QIAGEN GmbH GERMANY G.06

SARSTEDT AG & Co GERMANY G.08

Takara Bio Europe FRANCE G.05

Vela Diagnostics GERMANY G.31

Zymo Research Europe GmbH GERMANY G.20

A listing of support according to national compliance requirements can be found at

www.eurovirology2016.eu/fsa-list.html.

57

iHALL G

G.01

G.02

G.03

G.04

G.05

G.10 G.11

G.09

G.06

G.07

G.08

G.17

G.30 G.31

G.32G.29

G.26 G.27

G.28G.25

G.22 G.23

G.24G.21

G.15

G.16G.12

G.13G.14

G.18 G.19 G.20G.33

G.35

G.36

G.37

G.38

G.39

G.34

Entrance Entrance

Exhibition Floor Plan

58

6th European Congress of Virology

59

CloakroomHall 1

HALL A

HALL B

C1

C3

C2*

FOYERA-C

1st Floor

HALL 1

HALL G / EXHIBITION

FOYER HALL D-G

HALL F

HALL E

HALL D

FOYER HALL 1

Registration

2nd Floor

*Media Check

Congress Center Hamburg Overview

60

6th European Congress of Virology

Notes

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

61

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

62

6th European Congress of Virology

Notes

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

63

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .